Skrypski v. Sampson — Entry #79: Defendants ANSWER to 54 Amended Complaint by Barbara K
Case: Skrypski v. Sampson cod · 1:25-cv-00306
filed January 29, 2025
What this document is
Docket entry #79 · filed October 05, 2026
Defendants ANSWER to 54 Amended Complaint by Barbara K. Gutierrez, L. Heath Sampson, Kenneth Shepard.(Loseman, Monica) (Entered: 10/05/2026)
Who is involved
- Barbara K. Gutierrez
- Christopher Skrypski
- Dinesh Kalera
- Irving Firemens Relief and Retirement Fund
- Kenneth Shepard
- L. Heath Sampson
- LeKesh Pettis
- Matt Rose
- ModivCare, Inc.
Why we have it
We follow this case because it names a company we track, although that company is not a party:
- Riot: its former name “AspenBio Pharma, Inc.” appears in a filing in this case.
…........................... 3 Wolfe v. Aspenbio Pharma, Inc., 275 F.R.D. 625 (D. Colo. 2011) ...…
A free copy from the RECAP archive of federal court filings (mirrored at the Internet Archive), retrieved November 16, 2026. Federal court filings are public records.
Document text
269 page(s), 628,868 characters, converted from the PDF's text layer · plain text.
Full text
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 1 of 269
UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLORADO
Civil Action No. 1:25-cv-00306-GPG-KAS
CHRISTOPHER SKRYPSKI, individually
and on Behalf of All Others Similarly Situated,
Plaintiff,
v.
L. HEATH SAMPSON, KENNETH
SHEPARD, and BARBARA K.
GUTIERREZ,
Defendants.
DEFENDANTS’ ANSWER TO THE AMENDED CLASS ACTION COMPLAINT FOR
VIOLATIONS OF THE FEDERAL SECURITIES LAWS (DKT. 54)
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 2 of 269
Defendants L. Heath Sampson, Kenneth Shepard, and Barbara K. Gutierrez
(collectively, “Defendants”) submit this Answer to Plaintiff Christopher Skrypski’s
Amended Class Action Complaint for Violations of the Federal Securities Laws (the
“Amended Complaint”; Dkt. 54), filed on January 9, 2026.
The Court’s August 7, 2026 Order only addressed and allowed Plaintiff’s claims to
proceed with respect to the risk factor allegations found in Paragraphs 169–173, 177–
180, 184, 225, 244, and 278–281.* Defendants are not required to respond to allegations
that the Court has not determined are adequately alleged under the Private Securities
Litigation Reform Act of 1995, Abdo v. United States, 2024 WL 6473903, at *2 (D. Colo.
Dec. 5, 2024) (citing Nat’l Credit Union Admin. Bd. v. RBS Sec., Inc., 2013 WL 11332740,
at *5 (D. Kan. Oct. 24, 2013)), and, on that basis, deny those allegations. Except as
otherwise expressly stated herein, Defendants deny each and every claim, theory, and
allegation asserted in the Amended Complaint, and specifically deny liability under § 10(b)
and § 20(a) of the Securities Exchange Act of 1934 and U.S. Securities and Exchange
Commission (“SEC”) Rule 10b-5 promulgated thereunder. Pursuant to Rule 8(b)(6) of the
Federal Rules of Civil Procedure, averments in the Amended Complaint to which no
responsive pleading is required shall be deemed denied. Defendants expressly reserve
the right to amend and/or supplement this Answer as may be necessary.
*
Defendants understand that Plaintiff disagrees with this interpretation of the Court’s
August 7, 2026 Order. Defendants have filed a motion seeking clarification of the Court’s
Order. See Dkt. 74. Should answers to these allegations be required, Defendants have
provided them below. Defendants will also amend this Answer if the Court’s order on their
Motion for Clarification renders it necessary.
2
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 3 of 269
RESPONSE TO HEADINGS AND FOOTNOTES
The Amended Complaint contains several headings, which Defendants have
included in this Answer. The headings are not properly pleaded allegations requiring a
response, and Defendants do not adopt the characterizations set forth in those headings.
To the extent any headings contain allegations requiring a response, Defendants deny
the allegations set forth therein. Defendants also deny the allegations contained in the
footnotes from Lead Plaintiff’s Amended Complaint, except where they explicitly note
otherwise.
In answer to the Amended Complaint, Defendants state as follows:
RESPONSE TO INDIVIDUAL PARAGRAPHS IN THE AMENDED COMPLAINT
1. Lead Plaintiff Christopher Skrypski (“Lead Plaintiff” or “Plaintiff”) brings this class
action against Defendants (defined below) pursuant Sections 10(b) and 20(a) of the
Securities Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. §§ 78j(b) and 78t(a)
and Rule 10b-5, 17 C.F.R. § 240.10b-5, promulgated thereunder by the U.S.
Securities and Exchange Commission (“SEC”), individually and on behalf of himself
and all persons and entities similarly situated who purchased or otherwise acquired
ModivCare Inc. (“ModivCare” or the “Company”) securities between November 3,
2022 to September 15, 2024, inclusive (the “Class Period”).
ANSWER: Paragraph 1 states a legal conclusion to which no response from
Defendants is required. To the extent a response is required, Defendants admit that the
Court appointed Christopher Skrypski as Lead Plaintiff. Defendants further admit that this
is a putative class action lawsuit purporting to bring claims against L. Heath Sampson,
Barbara K. Gutierrez, and Kenneth Shepard under Sections 10(b) and 20(a) of the
Exchange Act and Rule 10b-5 promulgated thereunder. Except as expressly admitted,
Defendants deny the allegations in Paragraph 1.
3
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 4 of 269
2. Plaintiff alleges the following based upon personal knowledge as to himself and his
own acts, and upon information and belief as to all other matters. Plaintiff’s information
and belief is based on the investigation of his undersigned attorneys (“Lead Counsel”),
which included, among other things, review and analysis of: (i) public documents,
public filings, and wire and press releases published by and regarding ModivCare; (ii)
Defendants’ other public statements, including transcripts of interviews Defendants
participated in; (iii) interviews with individuals who are former employees of ModivCare;
(iv) reports of securities and financial analysts, news articles, and other commentary
and analysis concerning ModivCare and the industry in which the Company operates;
and (v) pertinent court filings.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the allegations regarding Plaintiff’s purported investigation described in
Paragraph 2, and deny them on that basis. Defendants further deny that any alleged
statement, knowledge, conduct, document, or omission allegedly attributable to one
defendant is attributable to another.
3. Lead Counsel’s investigation into the matters alleged herein is continuing, and many
relevant facts are known only to, or are exclusively within, the custody or control of
Defendants. Plaintiff believes that substantial additional evidentiary support will exist
for the allegations set forth herein after a reasonable opportunity for discovery.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the allegations regarding Lead Counsel’s investigation and “beliefs”
described in Paragraph 3, and deny them on that basis.
I. NATURE OF THE ACTION
4. Plaintiff brings this securities fraud class action alleging that, throughout the Class
Period, ModivCare’s Chief Executive Officer (“CEO”) L. Heath Sampson (“Sampson”),
the Company’s Chief Financial Officer (“CFO”) Barbara Guiterrez (“Guiterrez”), and
the CFO for the Company’s core non-emergency medical transport (“NEMT”)
business Kenneth Shepard (“Shepard”) knowingly or severely recklessly made
material misrepresentations to investors concerning the Company’s shared risk
capitated contracts’ ability to offset ModivCare’s increased transportation costs from
4
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 5 of 269
higher NEMT utilization by members. Defendants likewise made material
misrepresentations that overstated the quality of ModivCare’s NEMT services and
their cost-effectiveness for the Company, including with respect to a “multi-modal
strategic initiative” that was intended to diversify the transportation methods available
to members.
ANSWER: Paragraph 4 states legal conclusions to which no response from
Defendants is required. Defendants also need not respond to the allegations in Paragraph
4 to the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-
K and 10-Q risk disclosures, which are the only alleged misstatements that the Court
addressed in its August 7, 2026 Order (see Dkt. 67 at 5; see also Dkt. 74 at 2–3), and
Defendants deny them on that basis. Defendants deny that any alleged statement,
knowledge, conduct, document, or omission allegedly attributable to one defendant is
attributable to another. To the extent a response is required, Defendants admit that Heath
Sampson served as ModivCare’s Chief Executive Officer, that Barbara Gutierrez served
as ModivCare’s Chief Financial Officer beginning September 18, 2023, and that Kenneth
Shepard served as Chief Financial Officer of ModivCare’s NEMT segment. Except as
expressly admitted, Defendants deny the allegations in Paragraph 4.
5. ModivCare is a healthcare services company whose core business entails
coordinating and managing non-emergency medical transportation in the United
States for individuals who ModivCare refers to as “members.” The Company is paid
primarily by its members’ insurers, which ModivCare calls “payors” and who are state
Medicaid programs and managed care organizations (“MCOs”).
ANSWER: Defendants admit that ModivCare is a healthcare services company
that provides non-emergency medical transportation (“NEMT”) services; that the
individuals who use ModivCare’s services are referred to as “members”; and that
ModivCare is paid by “payors” that include private healthcare insurers, state Medicaid
5
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 6 of 269
programs, and managed care organizations. Except as expressly admitted, Defendants
deny the allegations in Paragraph 5.
6. During the COVID-19 pandemic, ModivCare’s members utilized fewer NEMT services
due to stay at home orders and a rise in telehealth. Despite this drop-off in utilization
(i.e., the rate at which ModivCare’s members use its NEMT services), the Company’s
profits soared as a result of how its contracts with payors were structured. Namely,
ModivCare’s contracts were predominantly full-risk capitated contracts that provided
the Company with a fixed per-member per-month (“PMPM”) fee for each of the payors’
eligible members irrespective of whether those members were utilizing the Company’s
services.
ANSWER: Defendants admit that, during the COVID-19 pandemic, ModivCare’s
members utilized fewer NEMT services due to stay at home orders and a rise in telehealth.
Defendants further admit that, both before, during, and after the COVID-19 pandemic,
ModivCare had full-risk capitated contracts that provided that payors pay a fixed amount
per member per month, and ModivCare assumes the responsibility of meeting the
covered healthcare-related transportation requirements for the eligible members in the
customer’s program, regardless of how many or how few times the member utilizes
ModivCare’s services (usage) or how much cost is incurred in providing those services
(fulfillment costs). Except as expressly admitted, Defendants deny the allegations in
Paragraph 6.
7. Given that under the full-risk contracts ModivCare would receive the same PMPM if
the Company was experiencing a surge in utilization from members (which had the
effect of reducing the profit margin considerably as transportation costs increased),
the Company began renegotiating to shift its full-risk contracts to shared risk contracts
as pandemic restrictions eased and ModivCare anticipated that payors’ members
would begin to increase their use of the Company’s NEMT services.
6
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 7 of 269
ANSWER: Defendants admit and allege that, after the COVID-19 pandemic,
ModivCare anticipated that utilization and costs for providing NEMT services would
increase. Defendants further admit that ModivCare and certain payors renegotiated
certain contracts from full-risk capitated contracts to shared-risk capitated contracts.
Except as expressly admitted, Defendants deny the allegations in Paragraph 7.
8. ModivCare claimed that, under the shared risk contracts, the Company’s PMPM would
be adjusted upward or downward (depending on the actual realized transportation
volumes or costs). The purpose of these adjustments was to purportedly guarantee
that the Company would earn a certain profit level regardless of how much payors’
members were using the services or how much transportation costs increased.
Conversely, ModivCare’s profits were also capped under these shared risk contracts,
meaning if the Company reached the profit threshold, it would rebate its payors for
such overages.
ANSWER: Defendants admit that certain shared-risk contracts include provisions
for reconciliations, risk corridors, and/or profit rebates, which allow for periodic
reconciliations between ModivCare and the payors based on actual costs and/or trip
volumes and may result in refunds to the payor (contract payables) if utilization and costs
are low, or additional payments due from the payor (contract receivables) if utilization or
costs are high. To the extent that Paragraph 8 characterizes or quotes from ModivCare’s
public filings, Defendants respectfully refer the Court to the complete documents, which
speak for themselves, and deny any allegations inconsistent therewith. Except as
expressly admitted, Defendants deny the allegations in Paragraph 8.
9. Thus, during the adjustment process for shared risk contracts, ModivCare determined
whether the profit threshold had been met or exceeded. If the profit threshold had not
been met, then the Company would generally record an asset (i.e., contract receivable)
for which it would seek additional payment from the payor. On the other hand, if the
7
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 8 of 269
profit threshold was exceeded, then ModivCare would record a liability (i.e., contract
payable) that would need to be paid to the payor.
ANSWER: Defendants admit that accrued contract payables primarily represent
overpayments and liability reserves on certain risk corridor, profit rebate and reconciliation
contracts, and contract receivables primarily represent underpayments and receivables
on certain risk corridor, profit rebate, and reconciliation contracts. Except as expressly
admitted, Defendants deny the allegations in Paragraph 9.
10. Throughout the Class Period, which begins on November 3, 2022, Sampson
relentlessly touted the shared risk contracts’ purported benefits for ModivCare and its
customers. Indeed, Sampson assured investors that, “because of” ModivCare’s
shared risk “contracts, we’re able to pass [increased transportation costs]
through to a lot of our customers” and further claimed “if utilization goes way up,
we’re going to share in that. If costs go up, we’re going to share in that. And
that’s the way these contracts work.” Sampson further vowed that ModivCare was
“going to get paid on” instances where “utilization is going up and we’re doing
more trips and... it’s more expensive to us[.]” Indeed, Sampson assured “it gets
put on the balance sheet, and then we’ll collect it over the next 3 to 6 months.”
As such, Sampson represented that ModivCare’s shared risk contracts were
“structured so we have a win-win[.]”
ANSWER: Defendants need not respond to the allegations in Paragraph 10 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. Paragraph 10 also states legal conclusions to which no response
from Defendants is required. To the extent a response is required, Paragraph 10
characterizes or quotes from ModivCare’s November 3, 2022 earnings call and Deutsche
Bank’s 31st Annual Leveraged Finance Conference on October 3, 2023. Defendants
8
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 9 of 269
respectfully refer the Court to the complete recordings from those events, which speak
for themselves, and deny any allegations inconsistent therewith. Defendants otherwise
deny the allegations in Paragraph 10.
11. Defendant Sampson repeated this mantra on at least 15 occasions during the Class
Period, and detailed exactly what “win-win” meant (i.e., ModivCare would “share in []
increased [transportation] costs” which would thereby “allow[] [the Company] to
really have stable rigid margins regardless of utilization and cost[,]” “add[] [an]
additional layer of predictability to [its] cash flow[,]” and create “more normalized
working capital[.]”).
ANSWER: Defendants need not respond to the allegations in Paragraph 11 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. Paragraph 11 also states legal conclusions to which no response
from Defendants is required. To the extent a response is required, Paragraph 11
characterizes or quotes from Defendant’s public statements, and Defendants respectfully
refer the Court to the complete recordings from those events, which speak for themselves,
and deny any allegations inconsistent therewith. Defendants otherwise deny the
allegations in Paragraph 11.
12. In addition, every quarterly report filed with the SEC on behalf of ModivCare, falsely
represented that “[t]here have been no material changes” to the Company’s
previously issued risk factors in addition to containing purported risk disclosures that
speculatively cautioned that, inter alia, “implementation of alternative payment
models[,]” changes in payment levels from ... third-party payors[,]” and “[d]elays
in collection, or non-collection, of our accounts receivable” “could adversely
affect” revenues[,]” “operations[,]” or “financial condition[.]”
9
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 10 of 269
ANSWER: Defendants need not respond to the allegations in Paragraph 12 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Paragraph 12 characterizes
or quotes from ModivCare’s Forms 10-Q or 10-K, and Defendants respectfully refer the
Court to the complete documents, which speak for themselves, and deny any allegations
inconsistent therewith. Defendants otherwise deny the allegations in Paragraph 12.
13. In reality, unbeknownst to investors, ModivCare’s true-up process under the shared
risk contracts persistently caused disputes with customers. For instance, CW2,
ModivCare’s Vice President (“VP”) of Transportation, confirmed that mismatches
between ModivCare’s internal utilization data and payors’ actual “encounter data”
caused payors to contend that they owed ModivCare far less than the Company
claimed. Rather than sharing in higher costs as Defendants’ claimed, ModivCare was
locked in disputes about how many trips members actually took, which had a
significant financial impact. Indeed, CW2 explained that such utilization discrepancies
could result in PMPM rates fluctuating $3 or more and would be multiplied across large
membership populations. According to CW2, ModivCare was subjected to monthly
liquidated damages for rejected encounter data and routinely forced to accept partial
payments as settlements as a result of the encounter related true-up disputes.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the confidential witness (“CW”) allegations in Paragraph 13 and deny them
on that basis. Defendants further deny that any alleged statement, knowledge, conduct,
document, or omission allegedly attributable to one defendant is attributable to another.
Defendants otherwise deny the allegations in Paragraph 13.
14. CW3 likewise stated that ModivCare faced significant disputes over risk corridors and
profits. CW3 provided an example where New Jersey—one of the Company’s largest
contracts—asserted that ModivCare had exceeded its profit cap and sought
10
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 11 of 269
repayment. CW3 confirmed that ModivCare was required to return a portion of those
profits to the state.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the CW allegations in Paragraph 14 and deny them on that basis.
Defendants otherwise deny the allegations in Paragraph 14.
15. ModivCare not only experienced disputes with customers concerning what was owed
to the Company under the shared risk contracts but also faced significant challenges
collecting new monthly PMPM payments from payors that ModivCare was in arrears
for as a result of previous utilization and mounting contract payables. For instance,
CW2 confirmed that such payors withheld monthly payments to offset the balance that
ModivCare owed to the payor. According to CW2, even where ModivCare conveyed
that payors needed to continue making monthly payments, payors refused— resulting
in disputes that dragged on for “a very long time.”
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the CW allegations in Paragraph 15 and deny them on that basis.
Defendants otherwise deny the allegations in Paragraph 15.
16. Despite ModivCare’s claims that its cash flow would become more normalized and
predictable through the shared risk contracts, the Company faced a significant cash
crunch. ModivCare’s working capital was affected by the rampant collectability issues
stemming from its true-up disputes as well as “repayments” that ModivCare elected to
make to payors who had paid hefty PMPMs during the Covid-19 pandemic despite
members’ low utilization. Indeed, ModivCare was shelling out hundreds of millions of
dollars in cash and drawing down on its revolving credit facility to pay down its
contracts payables balance while simultaneously facing a mounting contracts
receivables balance that was not coming in the door.
ANSWER: To the extent Paragraph 16 characterizes or quotes from ModivCare’s
public statements and disclosures regarding its cash flow, working capital, contracts
receivables and contracts payables balances, Defendants respectfully refer the Court to
the complete statements and documents, which speak for themselves, and deny any
11
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 12 of 269
allegations inconsistent therewith. Defendants otherwise deny the allegations in
Paragraph 16.
17. ModivCare’s collectability issues under the shared risk contracts were also
exacerbated by payors who, dissatisfied with the Company’s service and
technological shortcomings, placed the Company on performance improvement plans,
delayed payments, sought monthly liquidated damages, and canceled contracts.
Indeed, CWs confirmed that, prior to and continuing through the Class Period,
ModivCare received increasing complaints about its NEMT service, including driver
no shows and on-time performance issues, and about promised technological
enhancements, aimed at reducing those very complaints, that ModivCare had not
delivered.
ANSWER: Defendants need not respond to the allegations in Paragraph 17 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the allegations concerning
whether payors were “dissatisfied” with ModivCare and the CW allegations in Paragraph
17 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph
17.
18. For instance, CW3 stated ModivCare consistently failed to provide payors with the
technology and system maintenance offerings that the Company committed to
delivering in contracts, including ride scheduling, real-time reporting, GPS tracking,
and dynamic trip reassignment for medical appointments. As a result, according to
CW3, missed appointments and no-shows were significant service issues that
ModivCare had throughout CW3’s tenure that did not improve. CW3 further recalled
that ModivCare consistently failed to meet key performance indicators (“KPIs”),
including on-time performance, no vehicle available (“NVAs”) (which caused missed
12
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 13 of 269
rides), and call center complaints regarding delayed call answer, which affected most
payors.
ANSWER: Defendants need not respond to the allegations in Paragraph 18 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
18 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph
18.
19. CW3 also stated that ModivCare’s poor service delivery, long-standing weaknesses
in technology, and reliance on an outdated platform caused major contracts to be
under threat throughout September 2023 (i.e., the end of CW3’s tenure). Likewise,
CW2 stated that, beginning around the second quarter of 2022 (“2Q2022”) and
continuing throughout CW2’s tenure, ModivCare’s poor operational performance
(such as call center failures) led to client dissatisfaction and monthly liquidated
damages of hundreds of thousands of dollars. CW1 also stated that, during CW1’s
last year with ModivCare, the Company began losing NEMT contracts because
service levels “were way down” due to poor service quality and high employee
turnover. Indeed, CW1 stated during this time, payors were “literally cancelling
contracts because the service, and the people trying to perform the services, kept
changing so much. The service levels were way down.”
ANSWER: Defendants need not respond to the allegations in Paragraph 19 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
13
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 14 of 269
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
19 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph
19.
20. Customers were also dissatisfied with ModivCare’s multi-modal strategic initiative,
which was intended to reduce transportation costs and offset the impacts of increased
utilization. CWs confirmed that ModivCare’s multi-modal strategic initiative was
disliked by users and as a result, “fared very poorly” and failed to achieve forecasted
cost savings.
ANSWER: Defendants need not respond to the allegations in Paragraph 20 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the allegations concerning
unidentified “customers.” Defendants further lack knowledge or information sufficient to
form a belief as to the truth of the CW allegations in Paragraph 20 and deny them on that
basis. Defendants otherwise deny the allegations in Paragraph 20.
21. Nevertheless, Defendant Sampson professed that ModivCare was “meeting or
exceeding all [its] customers’ quality and service level requirements[,]” including “on-
time performance and reduced miss trips[,]” and touted that “[o]ur multimodal
transportation partnership strategy has led to increased customer satisfaction and
reduced costs.”
ANSWER: Defendants need not respond to the allegations in Paragraph 21 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
14
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 15 of 269
see also Dkt. 74 at 2–3. To the extent a response is required, Paragraph 21 characterizes
or quotes from ModivCare’s August 4, 2023 earnings call, and Defendants respectfully
refer the Court to the complete recording from that earnings call, which speaks for itself,
and deny any allegations inconsistent therewith. Defendants otherwise deny the
allegations in Paragraph 21.
22. Importantly, Defendants knew or recklessly disregarded that payors were dissatisfied
with ModivCare’s NEMT services and technological shortcomings, as well as the
shared risk contract disputes. For instance, during a May 2023 Summit, CW3
presented competitive analyses that showed, inter alia, long-standing weaknesses in
technology and poor service delivery, to Sampson and others in leadership. Likewise,
between March and May of 2023 and continuing throughout the Class Period,
Defendant Shepard (who was Defendant Sampson’s direct report) participated in
customer dispute calls regarding the shared risk contract that had escalated to a point
where such customers requested Shepard’s involvement. CWs also confirmed that
Defendants Sampson and Shepard attended regular meetings where rising service
complaints, contract de-implementations, missed KPIs, and results of the strategic
initiatives were discussed in detail, and received presentations regarding de-
implementations (which Defendants could also access “whenever they wanted”).
Defendants also admittedly monitored NEMT service data and regularly reported on
such information and the shared risk contracts in detail during public earnings calls
with investors. Moreover, as a result of his admittedly close relationships and frequent
discussions with payors’ executives regarding contracting and repricing, Sampson
also knew that payors were dissatisfied with ModivCare’s service levels and
technology offerings, were refusing to pay, delaying payments, and seeking liquidated
damages, refusing to share in increased costs under the shared risk contracts, and
cancelling contracts as a result of service and technology issues.
ANSWER: Defendants need not respond to the allegations in Paragraph 22 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Paragraph 22 states legal
15
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 16 of 269
conclusions to which no response is required. Defendants further lack knowledge or
information sufficient to form a belief as to the truth of the allegations concerning
unidentified “payors” and the CW allegations in Paragraph 22 and deny them on that
basis. Defendants further deny that any alleged statement, knowledge, conduct,
document, or omission allegedly attributable to one defendant is attributable to another.
Defendants otherwise deny the allegations in Paragraph 22.
23. The truth about ModivCare’s shared risk contracts and NEMT services issues was
gradually revealed to investors through a series of partial disclosures during the Class
Period, often as Defendants continued to simultaneously mislead investors. First, on
May 4, 2023, Defendants Sampson and Shepard revealed that ModivCare had a net
loss of $4.0 million for the first quarter of 2023 and had expended nearly $3 million in
cash as a result of a $7 million reduction in contract payables and $31 million increase
in contract receivables during the quarter. On this news, ModivCare’s common stock
price fell sharply, declining $11.30 per share, or approximately 16%, from $69.30 per
share on May 3, 2023 to $58.00 per share on May 4, 2023.
ANSWER: Paragraph 23 states legal conclusions to which no response is required.
To the extent a response is required, Defendants admit and allege that ModivCare’s
earnings and stock prices at various times are matters of public record and deny any
allegations inconsistent therewith. Paragraph 23 also characterizes or quotes from
ModivCare’s May 4, 2023 press release and earnings call. Defendants respectfully refer
the Court to the complete document or recording thereof, which speak for themselves,
and deny any allegations inconsistent therewith. Defendants further deny that any alleged
statement, knowledge, conduct, document, or omission allegedly attributable to one
defendant is attributable to another. Except as expressly admitted, Defendants deny the
allegations in Paragraph 23.
16
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 17 of 269
24. Next, on August 3, 2023 while reporting second quarter 2023 financials, ModivCare
slashed 2023 full-year Adjusted Earnings Before Interest, Taxes, Depreciation, and
Amortization (“EBITDA”) guidance due to, inter alia, “increased utilization and related
higher call volumes in NEMT,” and disclosed that the Company had used $108.2
million in cash and drew $126.5 million on its revolving credit facility due to “a
temporary timing mismatch between [NEMT] payments and collections” and $65
million in accelerated payments made to “a few large state clients” that “occurred
earlier than anticipated[.]” In response to this news, ModivCare’s common stock price
declined $2.86, or approximately 7%, from $38.24 per share on August 3, 2023, to
close at $35.38 per share on August 4, 2023.
ANSWER: Paragraph 24 states legal conclusions to which no response from
Defendants is required. To the extent a response is required, Defendants admit and allege
that ModivCare’s stock price at various times is a matter of public record and deny any
allegations inconsistent therewith. Paragraph 24 also characterizes or quotes from
ModivCare’s August 3, 2023 press release. Defendants respectfully refer the Court to the
complete document, which speaks for itself, and deny any allegations inconsistent
therewith. Except as expressly admitted, Defendants deny the allegations in Paragraph
24.
25. Then, on February 22, 2024, after the market closed, Defendants disclosed that
ModivCare’s free cash flow for fourth quarter 2023 and full year 2023 were negative
$36.8 million and negative $125.3 million, respectively, and the Company had drawn
$113.8 million from its revolving credit facility. ModivCare’s dismal financials stemmed
from NEMT “margin pressure” related to several contract losses, “sooner than
anticipated, large COVID-related working capital needs[,]” and a ~$35.9 million
delayed payment from a client. On this news, ModivCare’s common stock price fell
$17.25 per share, or approximately 39%, from a close of $43.87 on February 22, 2024
to a close of $26.62 on February 23, 2024 on heavy trading volume.
ANSWER: Paragraph 25 states legal conclusions to which no response from
Defendants is required. To the extent a response is required, Defendants admit and allege
that ModivCare’s stock price at various times is a matter of public record and deny any
17
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 18 of 269
allegations inconsistent therewith. Paragraph 25 also characterizes or quotes from
ModivCare’s February 22, 2024 press release and Form 8-K. Defendants respectfully
refer the Court to the complete documents, which speak for themselves, and deny any
allegations inconsistent therewith. Defendants further deny that any alleged statement,
knowledge, conduct, document, or omission allegedly attributable to one defendant is
attributable to another. Except as expressly admitted, Defendants deny the allegations in
Paragraph 25.
26. Analysts were caught off guard by Defendants’ contract loss disclosures. For instance,
in two reports issued on February 23, 2024 Deutsche Bank initially noted that the
“contract losses in NEMT” as “new information” while the later report noted that it was
“[m]ake or break time” for the Company. The analyst also stated in the first report that
“[w]ith several bumps on the road over the past year and struggles with FCF
generation, we are unable to continue recommending MODV and downgrade to a
Hold.” In the second report, the analyst added the “[m]ismatch between receivables
and payables has been a persistent cash flow headwind for MODV over the last year”
and the “lack of visibility into quarter to quarter performance of the shared risk contract
book and the aggressive operating leverage implied in the 2H quarters is likely to
result in investors taking a wait-and-see approach.”
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the allegations concerning the reaction of unidentified analysts in Paragraph
26 and deny them on that basis. Paragraph 26 characterizes or quotes from a Deutsche
Bank analyst report dated February 23, 2024, and Defendants respectfully refer the Court
to the complete document, which speaks for itself, and deny any allegations inconsistent
therewith. Defendants otherwise deny the allegations in Paragraph 26.
27. Nevertheless, even as late as August 8, 2024, when Defendants were already
renegotiating prepayment terms with its shared risk NEMT customers in an desperate
effort to bring cash in the door, Defendants Sampson and Guiterrez assured investors
that ModivCare’s shared risk contracts were “win-win ... from a margin and P&L
18
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 19 of 269
perspective[,]” and “working as designed and protecting the downside [risk] and
protecting the P&L[.]”
ANSWER: Defendants need not respond to the allegations in Paragraph 27 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Paragraph 27 characterizes
or quotes from ModivCare’s August 8, 2024 earnings call, and Defendants respectfully
refer the Court to the complete recording, which speaks for itself, and deny any allegations
inconsistent therewith. Defendants further deny that any alleged statement, knowledge,
conduct, document, or omission allegedly attributable to one defendant is attributable to
another. Defendants otherwise deny the allegations in Paragraph 27.
28. Only one month later, on September 12, 2024, contrary to Defendants’ misstatements
during the Class Period, Defendants revealed that “the Company has not offset the
existing and continued accumulation of receivables during the period” and though
“collection and mitigation efforts continue, there remains the possibility that the
Company will not achieve full resolution in a timely manner or at all if unforeseen
circumstances arise.” The Company’s further revealed that its annual report for the
year ended December 31, 2023, which was filed with the SEC on Form 10-K on
February 26, 2024 (“FY2023 10K”), was updated to reflect a “going concern.” In
response to this news, ModivCare’s common stock price declined $18.43, or
approximately 59%, from $31.19 per share on September 11, 2024 to $12.76 per
share on September 12, 2024 on heavy trading volume.
ANSWER: Paragraph 28 states legal conclusions to which no response from
Defendants is required. To the extent a response is required, Defendants admit and allege
that ModivCare’s stock price at various times is a matter of public record and deny any
allegations inconsistent therewith. Paragraph 28 also characterizes or quotes from
19
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 20 of 269
ModivCare’s September 12, 2024 Form 8-K. Defendants respectfully refer the Court to
the complete document, which speaks for itself, and deny any allegations inconsistent
therewith. Defendants further deny that any alleged statement, knowledge, conduct,
document, or omission allegedly attributable to one defendant is attributable to another.
Except as expressly admitted, Defendants deny the allegations in Paragraph 28.
29. Then, on September 16, 2024, Defendants revealed that ModivCare had “experienced
delays in the timely collection of approximately $60 million of its outstanding $159.3
million in NEMT segment current contract receivables, primarily from MCO customers,
as of June 30, 2024” (i.e., over a month before Defendants’ August 8, 2024
misstatements) and Defendants also slashed the Company’s 2024 Adjusted EBITDA
guidance range “primarily due to NEMT segment pricing accommodations made to
strategically retain and expand key customer relationships.” In response, ModivCare’s
common stock price fell $1.40, or nearly 10%, from a close of $14.12 per share on
September 13, 2024 to a close of $12.72 per share on September 16, 2024.
ANSWER: Paragraph 29 states legal conclusions to which no response from
Defendants is required. To the extent a response is required, Defendants admit and allege
that ModivCare’s stock price at various times is a matter of public record and deny any
allegations inconsistent therewith. Paragraph 29 characterizes or quotes from
ModivCare’s September 16, 2024 Form 8-K. Defendants respectfully refer the Court to
the complete document, which speaks for itself, and deny any allegations inconsistent
therewith. Defendants further deny that any alleged statement, knowledge, conduct,
document, or omission allegedly attributable to one defendant is attributable to another.
Except as expressly admitted, Defendants deny the allegations in Paragraph 29.
30. Analysts were shocked, particularly given the Company’s previous reticence to
provide details around the delayed payment dispute. For instance, a September 17,
2024 Barrington Research reduced its price target by $16, expressly highlighted that
the collectability concerns were “particularly troubling since the company had
20
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 21 of 269
explicitly stated in prepared remarks on its Q2 conference call in early August that it
had visibility into $60 million of near-term cash collections from a couple of its large
customers.” The report added that such “commentary contributed materially to our
decision to upgrade the shares six weeks ago and probably served as similar
comfort to many investors.”
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the allegations concerning the reaction of unidentified analysts in Paragraph
30 and deny them on that basis. Paragraph 30 characterizes or quotes from a Barrington
Research analyst report dated September 17, 2024, and Defendants respectfully refer
the Court to the complete document, which speaks for itself, and deny any allegations
inconsistent therewith. Defendants otherwise deny the allegations in Paragraph 30.
31. Defendants would later admit after the Class Period on November 7, 2024, ModivCare
planned to shift its shared risk contracts and the majority of the Company’s revenue
to fee-for-service (“FFS”) arrangements because the shared risk contracts were not
offering the Company or its customers a win-win but instead, because ModivCare had
been paid lower under the shared risk contacts and the true-up “costs were higher
than a lot of [ModivCare’s customers] expected[,]” “surprise[d] ... a lot of our payers”
“[a]nd that was painful.”
ANSWER: Paragraph 31 characterizes or quotes from ModivCare’s November 7,
2024 earnings call, and Defendants respectfully refer the Court to the complete recording,
which speaks for itself, and deny any allegations inconsistent therewith. Defendants
further deny that any alleged statement, knowledge, conduct, document, or omission
allegedly attributable to one defendant is attributable to another. Defendants otherwise
deny the allegations in Paragraph 31.
32. Defendants’ fraudulent and misleading statements served to artificially inflate the price
of ModivCare’s common stock throughout the Class Period, causing massive investor
losses when the price of the stock precipitously declined with each disclosure about
21
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 22 of 269
ModivCare’s shared risk contracts and service issues. Lead Plaintiff hereby seeks
damages individually and on behalf of the Class.
ANSWER: Paragraph 32 states legal conclusions to which no response from
Defendants is required. To the extent a response is required, Defendants deny the
allegations in Paragraph 32.
II. JURISDICTION AND VENUE
33. The claims asserted herein arise under §§ 10(b) and 20(a) of the Exchange Act, 15
U.S.C. § 78j(b) and § 78t(a), and Rule 10b-5 promulgated thereunder by the SEC, 17
C.F.R. § 240.10b-5.
ANSWER: Paragraph 33 states legal conclusions to which no response from
Defendants is required.
34. This Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. § 1331
and § 27 of the Exchange Act, 15 U.S.C. § 78aa.
ANSWER: Paragraph 34 states legal conclusions to which no response from
Defendants is required.
35. This Court has jurisdiction over each Defendant named herein because each
Defendant is an individual who has sufficient minimum contacts with this District to
render the exercise of jurisdiction by the District Court permissible under traditional
notions of fair play and substantial justice.
ANSWER: Paragraph 35 states legal conclusions to which no response from
Defendants is required.
36. Venue is proper in this Court pursuant to 28 U.S.C. § 1391(b) and § 27 of the
Exchange Act because many of the false and misleading statements were made in or
issued from this District. ModivCare is headquartered in this District, with its principal
place of business located at 6900 Layton Avenue, 12th Floor, Denver, Colorado 80237.
ANSWER: Paragraph 36 states legal conclusions to which no response from
Defendants is required. To the extent that these allegations are deemed to be factual,
22
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 23 of 269
Defendants admit that ModivCare’s principal place of business was located at 6900 E
Layton Avenue, 12th Floor, Denver, Colorado 80237, and that venue is proper in this Court.
Except as expressly admitted, Defendants deny the allegations in Paragraph 36.
III. PARTIES
A. Plaintiff
37. Court-appointed Lead Plaintiff Christopher Skrypski (“Lead Plaintiff” or “Plaintiff”)
purchased ModivCare common stock during the Class Period, as set forth in his
previously filed certification (ECF No. 17-1) and incorporated by reference herein, and
suffered damages as set forth herein.
ANSWER: Paragraph 37 states legal conclusions to which no response from
Defendants is required. To the extent a response is required, Defendants admit that the
Court appointed Christopher Skrypski as Lead Plaintiff. Defendants lack knowledge or
information sufficient to form a belief as to the truth of the remaining allegations in
Paragraph 37 and deny them on that basis. Except as expressly admitted, Defendants
deny the allegations in Paragraph 37.
B. Defendants
38. At all relevant times, Defendant L. Heath Sampson served as ModivCare’s President
and CEO as well as a Director on the Company’s Board of Directors (“Board”). Prior
to his appointment to such positions, Sampson was ModivCare’s Interim CEO
between August 1, 2022 and November 1, 2022 and its CFO between February 26,
2021 and September 18, 2023. Defendant Barbara Gutierrez succeeded Sampson as
ModivCare’s CFO. Sampson also led ModivCare’s Mobility (i.e., NEMT) business
between January 2022 and April 12, 2022, when he was succeeded by Ilias Simpson
as President of the Company’s Mobility division.
ANSWER: Defendants admit that Mr. Sampson served as ModivCare’s President
and Chief Executive Officer and as a member of ModivCare’s Board of Directors during
the alleged Class Period; that Mr. Sampson previously served as ModivCare’s Interim
23
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 24 of 269
Chief Executive Officer; and that Mr. Sampson served as ModivCare’s Chief Financial
Officer prior to and for part of the alleged Class Period. Defendants further admit that Mr.
Sampson previously led ModivCare’s Mobility division, and that he was succeeded by
Ilias Simpson as President of ModivCare’s Mobility division. Defendants also admit that
Ms. Gutierrez succeeded Mr. Sampson as Chief Financial Officer. Except as expressly
admitted, Defendants deny the allegations in Paragraph 38.
39. At all relevant times, Defendant Kenneth Shepard served as ModivCare’s CFO for the
Company’s NEMT business.
ANSWER: Defendants admit that Mr. Shepard served as Chief Financial Officer of
ModivCare’s NEMT segment during the alleged Class Period. Except as expressly
admitted, Defendants deny the allegations in Paragraph 39.
40. Defendant Barbara Gutierrez joined ModivCare on September 18, 2023 as the
Company’s CFO and held this position throughout the remainder of the Class Period.
On May 5, 2025, ModivCare announced Gutierrez’s employment was being
terminated effective May 31, 2025.
ANSWER: Defendants admit that Ms. Gutierrez was ModivCare’s Chief Financial
Officer from September 18, 2023 until May 31, 2025. Defendants further admit that, on
May 5, 2025, ModivCare filed a Form 8-K with the SEC announcing that Ms. Gutierrez
would depart the Company effective May 31, 2025. Except as expressly admitted,
Defendants deny the allegations in Paragraph 40.
41. Defendants Sampson, Shepard, and Gutierrez are collectively referred to herein as
the “Defendants.”
ANSWER: Paragraph 41 does not contain any factual allegations requiring a
response. To the extent a response is required, Defendants admit that the Amended
Complaint refers to Mr. Sampson, Mr. Shepard, and Ms. Gutierrez collectively as the
24
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 25 of 269
“Defendants.” Except as expressly admitted, Defendants deny the allegations in
Paragraph 41.
42. The Defendants, by virtue of their high-level positions at ModivCare, directly
participated in the management of ModivCare and were directly involved in the day-
to-day operations of ModivCare at the highest levels. As such, they were privy to
confidential, proprietary information concerning the Company and its business
operations, growth, and financial condition. As set forth below, the materially misstated
information conveyed to the public was the result of the individual and collective
actions of these individuals.
ANSWER: Paragraph 42 states legal conclusions to which no response from
Defendants is required. To the extent a response is required, Defendants deny the
allegations in Paragraph 42.
43. As senior executives at a publicly held company with securities registered with the
SEC and, throughout the Class Period, traded on the Nasdaq Global Select Market
(“NASDAQ”), the Defendants each had a duty to disseminate prompt, accurate, and
truthful information with respect to the Company’s business, operations, financial
statements, and internal controls, and to correct any previously issued statements that
were or had become materially misleading or untrue, so that the market price of
ModivCare’s publicly traded securities would be based on accurate information. Each
Defendant violated these requirements and obligations during the Class Period.
ANSWER: Paragraph 43 contains legal conclusions to which no response from
Defendants is required. To the extent a response is required, Defendants admit that
ModivCare’s common stock was registered with the SEC and traded on the Nasdaq
Global Select Market during the alleged Class Period. Except as expressly admitted,
Defendants deny the allegations in Paragraph 43.
44. As a result of their positions of control and authority as senior executives, the
Defendants were able to and did control the content of the public statements issued
by the Company during the Class Period. Each Defendant had the ability to correct
the statements or prevent them from being released into the public sphere.
25
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 26 of 269
Accordingly, the Defendants are responsible for the accuracy of the materially false
and misleading public statements detailed in this complaint.
ANSWER: Paragraph 44 contains legal conclusions to which no response from
Defendants is required. Defendants deny that any alleged statement, knowledge, conduct,
document, or omission allegedly attributable to one defendant is attributable to another.
To the extent a response is required, Defendants deny the allegations in Paragraph 44.
45. As a result of their positions of control and authority as senior executives, the
Defendants had access to adverse, undisclosed information about the Company’s
business, operations, financial statements, and internal controls through their access
to internal corporate documents and conversations with other corporate officers and
employees. Defendants knew or recklessly disregarded that the positive
representations they made about the Company were materially false and misleading
and material facts omitted from positive representations made by Defendants about
the Company rendered those representations materially false and misleading, as
detailed herein.
ANSWER: Paragraph 45 contains legal conclusions to which no response from
Defendants is required. Defendants deny that any alleged statement, knowledge, conduct,
document, or omission allegedly attributable to one defendant is attributable to another.
To the extent a response is required, Defendants deny the allegations in Paragraph 45.
C. Relevant Non-Parties
46. At all times relevant to this action, ModivCare was a public corporation, organized and
existing under the laws of the State of Delaware with its principal place of business
and principal executive offices located at 6900 Layton Avenue, 12th Floor, Denver,
Colorado 80237. Throughout the Class Period, the Company’s securities were traded
on the NASDAQ, a national exchange, under the ticker symbol “MODV.” On August
20, 2025, ModivCare filed for voluntary Chapter 11 bankruptcy protection. On August
28, 2025, the Company’s common stock was suspended from trading on the NASDAQ
and delisted. Thereafter, ModivCare’s common stock began trading on the over-the-
counter markets (“OTCMKTS”) under the ticker MODVQ.
26
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 27 of 269
ANSWER: Defendants admit that ModivCare was a corporation organized under
the laws of the State of Delaware with its principal place of business and principal
executive offices located at 6900 E Layton Avenue, 12th Floor, Denver, Colorado 80237;
that ModivCare’s common stock traded on the NASDAQ under the ticker symbol “MODV”
during the alleged Class Period; that ModivCare filed for voluntary protection under
Chapter 11 of the Bankruptcy Code on August 20, 2025; that ModivCare’s common stock
was delisted from trading on the NASDAQ on August 28, 2025; and that ModivCare’s
common stock thereafter traded on OTCMKTS under the ticker symbol “MODVQ.” Except
as expressly admitted, Defendants deny the allegations in Paragraph 46.
47. CW1 was a ModivCare employee from before the Class Period until Q3 2023. As part
of CW1’s responsibilities, CW1 managed the Company’s multi-million-dollar NEMT
contracts to provide transportation to payors’ members. CW1 was also responsible for
de-implementations, which refers to ending payors’ contracts with ModivCare.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the allegations concerning CW1 in Paragraph 47 and deny them on that
basis.
48. In CW1’s role, CW1 had access to all of the information regarding the Company’s
NEMT contracts, including the payors, the contracts’ dollar amount, the members, the
number of members for each contract, “and basically everything in the contract, to
understand what it would take for us to provide the service.”
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the allegations concerning CW1 in Paragraph 48 and deny them on that
basis.
49. CW1 was responsible for coordinating with upper management, including senior vice
presidents and presidents, at insurance and healthcare companies to set those payors
up on ModivCare’s system, help them understand the technology, and set the payor
27
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 28 of 269
up with the transportation providers that ModivCare works with in the states applicable
to the payors’ contract. According to CW1, ModivCare’s implementation phase for a
new payor typically lasted between 90 and 120 days but could last up to 9 months,
depending on the payor.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the allegations concerning CW1 in Paragraph 49 and deny them on that
basis.
50. CW1 also worked on ModivCare’s strategic initiatives with the Company’s operations
teams across the country to improve operational performance, start new initiatives to
improve operational efficiencies, and help the Home Health and NEMT divisions.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the allegations concerning CW1 in Paragraph 50 and deny them on that
basis.
51. CW2 served as ModivCare’s VP of Transportation before the Class Period and into
2024. CW2 was also responsible for overseeing profit and loss performance for all the
contracts in CW2’s region.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the allegations concerning CW2 in Paragraph 51 and deny them on that
basis.
52. CW2’s daily responsibilities included maintaining customer relationships, meeting
regularly with health plans, and ensuring that the Company was meeting contractual
metrics by reducing missed rides, increasing on-time performance, and improving
service delivery. CW2 also managed the network development team, which was
tasked with expanding provider networks and improving service delivery. As of
September 2022, CW2 reported to Senior VP of Transportation, Chris Heine, who
reported to the President of ModivCare’s Mobility Division, Illias Simpson. In CW2’s
role, CW2 had “tons” of meetings with the Senior VP of Transportation that were
largely focused on operations but occasionally involved financial discussions focused
on customers’ outstanding balances. CW2 also participated in Monthly Leadership
28
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 29 of 269
Meetings with the President of ModivCare’s Mobility Division and in general leadership
meetings with Defendant Sampson.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the allegations concerning CW2 in Paragraph 52 and deny them on that
basis.
53. CW3 was employed by ModivCare as a Director of Proposal Management and
Marketing Communication prior to the Class Period through April 2023 and as a Senior
Director of Proposal Management from April 2023 through September 2023. CW3
oversaw a team of approximately 12 employees who were responsible for identifying
and pursuing new contract opportunities nationwide, monitoring aggregated bid sites
for solicitations, preparing and submitting proposals, supporting the sales team with
pipeline and reporting information, and coordinating with other departments to develop
implementation plans for awarded contracts. CW3 initially reported to Senior VP of
Government Affairs Robert Pittman, then to Senior VP of Strategic Solutions Seth
Ravine.
ANSWER: Defendants admit and allege that CW3 is LeKesh Pettis. Dkt. 55.
Defendants lack knowledge or information sufficient to form a belief as to the truth of the
remaining allegations in Paragraph 53 and deny them on that basis. Except as expressly
admitted, Defendants deny the allegations in Paragraph 53.
IV. SUBSTANTIVE ALLEGATIONS
A. ModivCare is a Healthcare Services Company Whose Core Business
is Providing Non-Emergency Medical Transportation
54. ModivCare purports to be a technologically-enabled healthcare services company that
offers NEMT services, personal care services (“PCS”) and remote patient monitoring
solutions (“RPM”) throughout the United States. During the Class Period, ModivCare
had four reportable business segments: NEMT, PCS, RPM, and Corporate and Other.
The Company and its employees would sometimes refer to its NEMT business
segment as its Mobility division, and its PCS and RPM businesses as its Home division.
ANSWER: Defendants admit that, during the alleged Class Period, ModivCare
was a technology-enabled healthcare services company that provided non-emergency
29
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 30 of 269
medical transportation, personal care services, and remote patient monitoring solutions
in the United States; that ModivCare had four reportable segments: NEMT, Personal Care
Services, Remote Patient Monitoring, and Corporate and Other; and that ModivCare
referred to its NEMT segment as its Mobility division and to its Personal Care Services
and Remote Patient Monitoring segments collectively as its Home division. To the extent
Paragraph 54 characterizes or quotes from ModivCare’s public statements or other SEC
filings, Defendants respectfully refer the Court to the complete documents, which speak
for themselves, and deny any allegations inconsistent therewith. Except as expressly
admitted, Defendants deny the allegations in Paragraph 54.
55. ModivCare’s core business is NEMT, which consists of coordinating and managing
non-emergency medical transportation services. The Company generates the vast
majority of its revenue from NEMT services. For instance, in its financial and
operational report for the fourth quarter and full year ended December 31, 2024, which
was filed with the SEC on March 6, 2025 on Form 10-K (the “FY2024 Form 10-K”),
ModivCare reported the following net service revenues:
ANSWER: Defendants admit that, during the alleged Class Period, NEMT was one
segment of ModivCare’s business and that ModivCare filed its FY2024 Form 10-K with
the SEC on March 6, 2025. Paragraph 55 characterizes or quotes from ModivCare’s
FY2024 Form 10-K, and Defendants respectfully refer the Court to the complete
document, which speaks for itself, and deny any allegations inconsistent therewith.
Except as expressly admitted, Defendants deny the allegations in Paragraph 55.
30
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 31 of 269
56. The Company purports to be the largest manager of NEMT programs for state
governments and managed care organizations in the United States. During the Class
Period, ModivCare provided NEMT services in 48 states and the District of Columbia
to approximately between 33.6 and 36 million members. To facilitate this, ModivCare
partners with credentialed transportation providers, including third-party transportation
providers, on-demand transportation companies, mass transit entities, mileage
reimbursement programs, taxis, and county-based emergency medical service
providers, to supply transportation tailored to members individualized health needs.
The members are typically Medicaid or Medicare eligible and have limited mobility or
financial resources.
ANSWER: Defendants admit that, during the alleged Class Period, ModivCare
was the United States’s largest manager of NEMT programs for state governments and
managed care organizations; that ModivCare provided NEMT services in 48 states and
the District of Columbia; that ModivCare provided NEMT services through a network of
credentialed third-party transportation providers using a variety of transportation modes;
and that members were typically eligible for Medicaid or Medicare. Paragraph 56
characterizes or quotes from ModivCare’s public statements and SEC filings, and
Defendants respectfully refer the Court to the complete recordings or documents, which
speak for themselves, and deny any allegations inconsistent therewith. Except as
expressly admitted, Defendants deny the allegations in Paragraph 56.
B. ModivCare’s NEMT Customers Largely Consists of State Medicaid
Programs and MCOs
57. For its NEMT business, ModivCare’s customers primarily consist of state Medicaid
programs and MCOs, the latter of which are health plans (such as Medicare
Advantage) or healthcare companies that manage the delivery of healthcare services
to its members while aiming to balance costs with maintaining quality service. The
Company contracts with these customers (sometimes referred to as “payors”) to
provide NEMT services to the payors’ members. The Company’s top 6 payors
included UnitedHealthcare, Aetna, Humana, Anthem, Health Care Service
Corporation (“HCSC”) and Centene.
31
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 32 of 269
ANSWER: Defendants admit that, during the alleged Class Period, ModivCare’s
NEMT customers included state Medicaid programs, managed care organizations, and
healthcare companies; that ModivCare’s customers were referred to as payors; and that
ModivCare contracted with those payors to provide NEMT services to their members.
Except as expressly admitted, Defendants deny the allegations in Paragraph 57.
58. According to the Company’s FY2024 Form 10-K, ModivCare enters contracts with
state Medicaid contracts that generally cover a three-to-five-year period and contain
“multiple renewal options.” By contrast, ModivCare’s contracts with MCOs typically
continue until either party, with reasonable notice, terminates the agreement, and
purportedly “allow for regular price adjustments based upon utilization and
transportation cost.” Utilization refers to the rate at which ModivCare’s customers’
members use the Company’s NEMT services. The Company reports utilization as a
monthly average and on a quarterly basis.
ANSWER: Defendants admit that, during the alleged Class Period, certain of
ModivCare’s state Medicaid contracts generally covered a three-to-five-year period and
that certain of ModivCare’s contracts with MCOs continued until either party terminated
the contract. Defendants further admit and allege that utilization referred to the rate at
which members used ModivCare’s NEMT services and that ModivCare disclosed
utilization quarterly. Paragraph 58 characterizes or quotes from ModivCare’s FY2024
Form 10-K, and Defendants respectfully refer the Court to the complete document, which
speaks for itself, and deny any allegations inconsistent therewith. Except as expressly
admitted, Defendants deny the allegations in Paragraph 58.
59. ModivCare overwhelmingly derived its NEMT revenue from Medicaid contracts.
Indeed, according to the Company’s February 22, 2024 investor presentation (the
“4Q2023 Investor Presentation”) and March 6, 2025 investor presentation (the
“4Q2024 Investor Presentation”), approximately 83%, 82% and 85% of NEMT
revenue in 2022, 2023 and 2024, respectively, was attributable to Medicaid contracts.
32
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 33 of 269
The remaining revenue was generated from Medicare contracts. This revenue
breakdown remained consistent throughout the Class Period.
ANSWER: Defendants admit that, during the alleged Class Period, ModivCare
received revenue from its Medicaid contracts. Paragraph 59 characterizes or quotes from
ModivCare’s February 22, 2024 and March 6, 2025 investor presentations, and
Defendants respectfully refer the Court to the complete documents, which speak for
themselves, and deny any allegations inconsistent therewith. Except as expressly
admitted, Defendants deny the allegations in Paragraph 59.
60. ModivCare also earns a significant portion of its NEMT revenue from a small number
of key customers. For instance, according to ModivCare’s FY2024 Form 10-K, a single
state Medicaid agency accounted for around 10.9%, 11.2%, and 10.9% of the
Company’s NEMT revenue in 2022, 2023, and 2024, respectively. ModivCare earned
approximately 19.8%, 19.8%, and 22.4% of its NEMT revenue in 2022, 2023, and
2024 from its next four largest NEMT customers combined.
ANSWER: Paragraph 60 characterizes or quotes from ModivCare’s FY2024 Form
10-K, and Defendants respectfully refer the Court to the complete document, which
speaks for itself, and deny any allegations inconsistent therewith. Except as expressly
admitted, Defendants deny the allegations in Paragraph 60.
C. ModivCare Primarily Utilizes Three Contract Structures for its NEMT
Customers
61. ModivCare primarily utilizes three contract structures for its NEMT customers: (i)
capitated full-risk; (ii) capitated shared risk; and (iii) fee-for-service.
ANSWER: Defendants admit that, during the alleged Class Period, ModivCare
used capitated full-risk contracts, capitated shared-risk contracts, and fee-for-service
contracts with its NEMT customers. Except as expressly admitted, Defendants deny the
allegations in Paragraph 61.
33
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 34 of 269
62. Under both capitated contracts and fee-for-service structures, ModivCare arranges for
transportation of members through its network of independent transportation providers,
whereby ModivCare negotiates rates and remits payment to the transportation
providers. According to the Company’s FY2024 Form 10-K, to determine the per ride
or per mile rates paid under its transportation service contracts, ModivCare purports
to use pricing models for specific populations that “take into account factors such as
estimated utilization, state specific data, previous experience in the state or with
similar services, the medically covered programs outlined in the contract, identified
populations to be serviced, estimated volume, estimated transportation provider rates
and availability of mass transit.”
ANSWER: Defendants admit that, during the alleged Class Period, under either
capitated or fee-for-service contracts, ModivCare arranged transportation through a
network of independent transportation providers with which it negotiated rates and to
which it remitted payment. Defendants further admit and allege that, during the alleged
Class Period, ModivCare used pricing models that considered specific factors for specific
populations to determine applicable contract rates. Paragraph 62 characterizes or quotes
from ModivCare’s FY2024 Form 10-K, and Defendants refer the Court to the complete
document, which speaks for itself, and deny any allegations inconsistent therewith.
Except as expressly admitted, Defendants deny the allegations in Paragraph 62.
1. Full-Risk and Shared Risk Capitated Contracts
63. Capitation refers to “a health care payment method in which medical providers or
health plan administrators are paid a pre-determined dollar amount for each patient
assigned to them, regardless of how much medical care they provide to that patient.”1
Under this payment method, providers are incentivized to provide all of the necessary
care to a patient for a total cost under the capitated rate for said patient so that the
provider can retain difference in cost as profit.
1
[Footnote 1 in Complaint] “What is capitation?”,
https://www.healthinsurance.org/glossary/capitation/ (last accessed Jan. 9, 2026).
34
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 35 of 269
ANSWER: Paragraph 63 and footnote 1 state legal conclusions to which no
response from Defendants is required. To the extent a response is required, Defendants
admit that, during the alleged Class Period, under ModivCare’s capitated contracts,
payors paid a fixed amount per eligible member. Defendants lack knowledge or
information sufficient to form a belief as to the truth of the allegations regarding the
incentives of unidentified providers, and deny them on that basis. Except as expressly
admitted, Defendants deny the allegations in Paragraph 63 and footnote 1.
64. For both its full-risk and shared risk capitated contracts, ModivCare receives a fixed
PMPM for eligible members in a specific geography. ModivCare negotiates the fixed
PMPM fee with its customers during the bidding process, and purports to base this
figure on “actual historical transportation data for the subject geographic region as
provided by the payor, actuarial work performed in-house as well as by third party
actuarial firms and actuarial analysis provided by the payor.”
ANSWER: Defendants admit that, during the alleged Class Period, for both its
capitated full-risk and capitated shared risk contracts, ModivCare received a fixed per-
member per-month fee for eligible members in a specified geography. Defendants further
admit that, during the alleged Class Period, ModivCare determined the per-member per-
month fee with payors during the bidding process, and the fee was based on actual
historical transportation data for the subject geographic region as provided by the payor,
actuarial work performed in-house as well as by third party actuarial firms, and actuarial
analysis provided by the payor. Paragraph 64 characterizes or quotes from ModivCare’s
FY2024 Form 10-K, and Defendants respectfully refer the Court to the complete
document, which speaks for itself, and deny any allegations inconsistent therewith.
Except as expressly admitted, Defendants deny the allegations in Paragraph 64.
35
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 36 of 269
65. For its capitated full-risk contracts, ModivCare receives a pre-negotiated, fixed fee
from a payor for each of the payor’s eligible members per month and is responsible
for providing NEMT services to each of those members, regardless of the actual cost
of care. This means that, under capitated full-risk contracts, ModivCare receives the
same PMPM fee for a member who does not use any NEMT services during the month
as it does for a member who frequently uses NEMT services during the month. As
such, ModivCare’s revenue under its full-risk contracts fluctuates based on costs and
utilization. (i.e., the rate at which members use ModivCare’s NEMT services, or paid
trips per member).
ANSWER: Defendants admit that, during the alleged Class Period, under its
capitated full-risk contracts, ModivCare received a pre-negotiated, fixed per-member per-
month fee for each eligible member and assumed responsibility for the cost of service.
Except as expressly admitted, Defendants deny the allegations in Paragraph 65.
66. With capitated shared risk contracts, the Company also receives an upfront fixed fee
from a payor for each of the payor’s eligible members per month, but after the monthly
ridership per member is determined, the PMPM fee adjusted through a true-up
process to account for the actual realized transportation volumes or costs that may
result in refunds to the payor (contract payables), or additional payments due from the
payor (contract receivables) based on the contractually agreed upon provisions. As
such, the PMPM fee obtained by ModivCare increases or decreases based on
transportation costs and utilization. CW3 explained that ModivCare’s capitated shared
risk contracts varied by customer and used historical utilization data as the basis to
structure each agreed upfront payment by mapping out a risk-sharing plan tied to
those past trends.
ANSWER: Defendants admit that, during the alleged Class Period, under
ModivCare’s capitated shared risk contracts, the per-member per-month fee was subject
to a process that adjusted the fee based on actual realized transportation volumes or
costs and may have resulted in a contract payable or a contract receivable. Defendants
lack knowledge or information sufficient to form a belief as to the truth of the CW
36
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 37 of 269
allegations in Paragraph 66 and deny them on that basis. Except as expressly admitted,
Defendants deny the allegations in Paragraph 66.
67. ModivCare offered three different reconciliations provisions for its capitated shared
risk contracts: (i) reconciliation; (ii) risk corridor; and (iii) profit rebate.
ANSWER: Defendants admit that, during the alleged Class Period, ModivCare’s
capitated shared risk contracts may have contained reconciliation, risk corridor, or profit
rebate provisions. Except as expressly admitted, Defendants deny the allegations in
Paragraph 67.
68. For capitated contracts with reconciliation provisions, ModivCare receives a partial
payment as prepayment during the month that the service is provided. The
prepayments are periodically reconciled against actual trip volume and costs. Thus,
under a reconciliation provision, ModivCare could either issue a refund to customers
or receive additional payments depending on a comparison of the PMPM fee with the
actual cost and/or utilization.
ANSWER: Defendants admit that, during the alleged Class Period, under its
capitated contracts with reconciliation provisions, ModivCare received monthly capitation
payments as prepayments that were periodically reconciled against actual trip volume
and costs, which may have resulted in a refund to the customer or an additional payment
to ModivCare. Except as expressly admitted, Defendants deny the allegations in
Paragraph 68.
69. With capitated contracts that contain a risk corridor provision, ModivCare and a payor
negotiate and agree to allow profit within a certain corridor and once those thresholds
are met, the Company stops recognizing revenue.2 Therefore, through this provision,
2
[Footnote 2 in Complaint] “‘Risk corridors’ set limits on the dollar amount of risk or gain
that may be experienced for individual patients, e.g., 10% to 20% above or below
capitation payments.” Goodson et al., The Future of Capitation, J Gen Intern Med. 2001
Apr;16(4):250–256, https://pmc.ncbi.nlm.nih.gov/articles/PMC1495203/#ref-list1 (last
accessed Jan. 9, 2026).
37
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 38 of 269
ModivCare may record an asset (i.e., contract receivable) or liability (i.e., contract
payable). For instance, if the Company fails to meet the minimum profit established in
the corridor, it records a contract receivable and should receive additional payment
from the customer to reach that minimum threshold. On the other hand, if the
Company reaches the threshold or maximum, then ModivCare will not recognize any
additional revenue but instead, records a contract payable and will either reduce that
amount via future increases in trip volume or periodic settlements with the customer.
ANSWER: Defendants admit that, during the alleged Class Period, under its
capitated contracts with risk corridor provisions, ModivCare and the customer agreed to
allow profit within a certain corridor, and that ModivCare ceased recognizing revenue
once the threshold had been met. Defendants further admit that, during the alleged Class
Period, such contracts may have resulted in ModivCare recording a contract receivable
or a contract payable. Except as expressly admitted, Defendants deny the allegations in
Paragraph 69 and footnote 2.
70. For capitated contracts with profit rebate provision, ModivCare and a payor negotiate
and agree to a maximum profit and once that threshold is met, the Company stops
recognizing revenue. Thus, a profit rebate provision can only result in ModivCare
recording a contract payable.
ANSWER: Defendants admit that, during the alleged Class Period, under its
capitated contracts with profit rebate provisions, ModivCare and the payor may have
agreed to a maximum profit threshold, and ModivCare ceased recognizing revenue once
that threshold had been reached. Except as expressly admitted, Defendants deny the
allegations in Paragraph 70.
71. Accordingly, depending on the contract’s true-up provisions, ModivCare’s capitated
shared risk contracts purportedly allowed the Company and its payor to share the risk
of increases in costs and utilization, and featured the lowest gross margin variance of
the Company’s contracts. Indeed, the Company claimed that the shared risk contracts
38
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 39 of 269
would result in margin stabilization since the PMPM fee received would be adjusted
for the costs to provide the transportation services (see Figure 1 infra).
ANSWER: Defendants admit that, during the alleged Class Period, the structure
of ModivCare’s shared-risk capitated contracts allowed for margin stabilization as
generally the amount received per-member, per-month was adjusted for the costs to
provide the transportation services. Paragraph 71 and Figure 1 characterize or quote from
ModivCare’s public statements and SEC filings, including its February 22, 2024 investor
presentation, and Defendants respectfully refer the Court to the complete recordings or
documents, which speak for themselves, and deny any allegations inconsistent therewith.
Except as expressly admitted, Defendants deny the allegations in Paragraph 71.
2. Fee-for-Service Contracts
72. ModivCare also utilizes fee-for-service (“FFS”) contracts in its NEMT business,
wherein the Company charges specific fees for each NEMT service that it provides to
39
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 40 of 269
a payor’s members. Under this contract structure, the Company agrees to provide
services based on costs incurred plus a negotiated margin. Similar to capitated full-
risk contracts, the Company is entirely responsible for the costs associated with
providing the services and must estimate its costs when determining fees. The fees
are based on billing rates for specific services or defined membership populations.
ANSWER: Defendants admit that, during the alleged Class Period, ModivCare
utilized fee-for-service contracts where ModivCare payors paid a pre-arranged specified
amount for each service that ModivCare provided, and these specified amounts were
based on billing rates for specific services or defined membership populations. Except as
expressly admitted, Defendants deny the allegations in Paragraph 72.
73. ModivCare bills and collects a specified amount for each service provided. The FFS
revenue is recognized during the period in which the services are rendered and is
reduced by the estimated impact of contractual allowances and policy discounts for
certain third-party payors.
ANSWER: Defendants admit that, during the alleged Class Period, under its fee-
for-service contracts, ModivCare billed and collected a specified amount for each service
provided, and that revenue under the fee-for-service contracts was recognized in the
period in which the services were rendered. Except as expressly admitted, Defendants
deny the allegations in Paragraph 73.
D. After ModivCare Secures a NEMT Contract, the Company’s
Implementations Team Handles Customer Onboarding
74. ModivCare’s Implementations Team managed customer onboarding after the
Company obtained a new NEMT customer contract. CW1 provided an example of the
implementation process using Cigna Healthcare, explaining that if Cigna needed to
have transportation set up in Sacramento, California for 2,000 members by November
1st, then the Implementation team would “do everything it takes” to have
transportation arranged for those members, including setting up metrics that the payor
and ModivCare would track in connection with ModivCare providing the payors’
members transportation services, including member satisfaction, responsiveness to
40
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 41 of 269
complaints, how quickly transportation providers pick up the phone, length of time
members remained on the phone with transportation providers, response times, and
other KPIs. According to CW1, ModivCare’s implementation phase for a new payor
typically lasted between 90 and 120 days but could last up to 9 months, depending on
the payor.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the CW allegations in Paragraph 74 and deny them on that basis.
Defendants otherwise deny the allegations in Paragraph 74.
75. According to CW1, the Implementation team tracked utilization during the first 30 days
after a payor’s implementation was complete after which the responsibility for tracking
utilization transitioned to the Operations team. CW1 explained that utilization was
definitely a metric that ModivCare tracked carefully.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the CW allegations in Paragraph 75 and deny them on that basis.
Defendants otherwise deny the allegations in Paragraph 75.
E. During the COVID-19 Pandemic, ModivCare Experienced a Boon from
Full Risk Contracts with Low Utilization Which Spurred a Series of
Costly Acquisitions
76. Prior to the Class Period, in 2020, ModivCare’s contracts were predominantly
capitated full-risk with approximately 60% of its NEMT revenue derived from such
contracts. During this time, ModivCare experienced low utilization rates due to the
COVID-19 pandemic because its customers’ members were making less trips as a
result of the mandated stay at home orders and rise in telehealth visits.
ANSWER: Paragraph 76 characterizes ModivCare’s contracts and public
disclosures regarding its NEMT revenue, and Defendants respectfully refer the Court to
the complete documents, which speak for themselves, and deny any allegations
inconsistent therewith. Defendants otherwise deny the allegations in Paragraph 76.
77. For instance, CW2 explained that ModivCare’s full-risk contracts were extremely
lucrative during the COVID-19 pandemic because the Company collected millions of
41
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 42 of 269
dollars in PMPM payments but had virtually no transportation costs due to decreased
utilization as members remained at home. As a result, according to CW2, ModivCare
experienced a financial boon during the first approximately two years of the COVID-
19 pandemic.
ANSWER: Defendants lack knowledge or information sufficient to form a belief as
to the truth of the CW allegations in Paragraph 77 and deny them on that basis.
Defendants otherwise deny the allegations in Paragraph 77.
78. Indeed, according to the Company’s financial report for the fourth quarter and full year
ended December 31, 2020, which was filed with the SEC on March 1, 2021 on Form
10-K (the “FY2020 Form 10-K”), ModivCare reported that its 2020 NEMT operating
income totaled approximately $120,689,000, which was an approximately 488%
increase from the $24,732,000 reported for its 2019 NEMT operating income. The
Company primarily attributed the massive increase in NEMT operating income to
significantly lower service expenses, which were approximately $1,036,288,000 in
2020 as compared to approximately $1,401,152,000 in 2019.
ANSWER: Defendants admit that ModivCare filed its FY2020 Form 10-K with the
SEC on March 1, 2021. Paragraph 78 characterizes or quotes from ModivCare’s FY2020
Form 10-K, and Defendants respectfully refer the Court to the complete document, which
speaks for itself, and deny any allegations inconsistent therewith. Except as expressly
admitted, Defendants deny the allegations in Paragraph 78.
79. ModivCare’s NEMT operating income remained elevated during 2021 as compared to
2019 pre-COVID levels. For instance, according to the Company’s financial report for
the fourth quarter and full year ended December 31, 2021, which was filed with the
SEC on March 1, 2021 on Form 10-K (the “FY2021 Form 10-K”), ModivCare reported
that its 2021 NEMT operating income totaled approximately $73,121,000, which was
an approximately 196% increase from the $24,732,000 reported for its 2019 NEMT
operating income:3
3
[Footnote 3 in Complaint] ModivCare’s increased net service revenues also included
$110.0 million of revenue related to contracts from the National MedTrans, LLC
acquisition that took place in the second quarter of 2020.
42
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 43 of 269
ANSWER: Defendants admit that ModivCare filed its FY2021 Form 10-K with the
SEC on March 1, 2022. Paragraph 79, footnote 3, and Plaintiff’s chart characterize or
quote from ModivCare’s FY2021 Form 10-K, and Defendants respectfully refer the Court
to the complete document, which speaks for itself, and deny any allegations inconsistent
therewith. Except as expressly admitted, Defendants deny the allegations in Paragraph
79, footnote 3, and Plaintiff’s chart.
80. Indeed, ModivCare’s executives would later acknowledge that the COVID-19
pandemic provided a financial windfall to the Company. For example, at the 2023
Deutsche Bank Conference on October 3, 2023, Defendant Sampson stated:
[D]uring COVID, obviously, there wasn’t a lot of trips … So we
benefited heavily from increased cash coming into our
balance sheet as well as on the P&L as well, but the big
bolus was on our balance sheet.
ANSWER: Paragraph 80 characterizes or quotes from ModivCare’s October 3,
2023 Deutsche Bank conference transcript, and Defendants respectfully refer the Court
to the complete recording from that conference, which speaks for itself, and deny any
allegations inconsistent therewith. Defendants otherwise deny the allegations in
Paragraph 80.
43
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 44 of 269
81. ModivCare utilized its cash surplus along with a series of private senior note
placements to make a number of acquisitions between 2020 through 2022 that totaled
over a billion dollars. For instance, according to ModivCare’s FY2024 Form 10-K: (i)
in 2020, the Company acquired National MedTrans, LLC for $80 million and OEP AM,
Inc. (“Simplura”) for $575 million; (ii) in 2021, ModivCare spent over $650 million on
acquisitions, purchasing WellRyde, Care Finders Total Care, and VRI Intermediate
Holdings; and (iii) in 2022, the Company purchased personal care customer contracts
from another entity for $7.6 million and also acquired Guardian Medical Monitoring for
$71.6 million. These acquisitions were intended to grow ModivCare’s Mobility and
Home divisions while creating opportunities for cross-selling services and meeting
payor’s desires for a one-stop shop.
ANSWER: Defendants admit that ModivCare acquired National MedTrans, LLC
and OEP AM, Inc. in 2020; WellRyde, Care Finders Total Care, and VRI Intermediate
Holdings in 2021; and personal care customer contracts and Guardian Medical Monitoring
in 2022, in each case for the amount reported in ModivCare’s SEC filings. Paragraph 81
characterizes or quotes from ModivCare’s FY2024 Form 10-K. Defendants respectfully
refer the Court to the complete document, which speaks for itself, and deny any
allegations inconsistent therewith. Except as expressly admitted, Defendants deny the
allegations in Paragraph 81.
F. Leading Up to the Class Period, ModivCare Shifts from Capitated Full-
Risk Contracts to Primarily Capitated Shared Risk Contracts
82. After the COVID-19 lockdowns, the Company began to renegotiate its NEMT
contracts to shift away from capitated full-risk to capitated shared risk.
ANSWER: Defendants admit that ModivCare and certain payors renegotiated
certain NEMT contracts from full-risk capitated contracts to shared-risk capitated
contracts. Except as expressly admitted, Defendants deny the allegations in Paragraph
82.
44
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 45 of 269
83. Prior to that shift, the Company’s revenue from full-risk and shared risk capitated
contracts was approximately 60% and 25%, respectively. By 2Q 2021, ModivCare
reported that, of the approximately 85% of NEMT revenue that was capitated (with the
remaining 15% of NEMT revenue being FFS), approximately 44% and 41% were
attributable to full-risk and shared risk, respectively. ModivCare’s capitated NEMT
revenue remained divided roughly in half between full-risk and shared risk capitated
contracts, respectively, until the beginning of the Class Period. By 1Q 2023,
ModivCare reported that, of the approximately 85% of NEMT revenue that was
capitated, approximately 20% and 65% were attributable to full-risk and shared risk,
respectively.
ANSWER: Paragraph 83 characterizes or quotes from ModivCare’s public
statements and SEC filings regarding its NEMT revenue, and Defendants respectfully
refer the Court to the complete recordings or documents, which speak for themselves,
and deny any allegations inconsistent therewith. Defendants otherwise deny the
allegations in Paragraph 83.
84. This transition from capitated full-risk to shared risk contracts had significant
implications for ModivCare’s balance sheet because, as described in §IV.C.1 supra,
those contracts contained reconciliation, risk corridor, or profit rebate provisions that
could result in the Company booking a contract receivable or contract payable
depending on service costs and member utilization. For instance, prior to the Class
Period during the Company’s June 23, 2022 inaugural Investor Day (the “2022
Investor Day”), Sampson explained that ModivCare “expect[ed]” contracts payable
and contracts receivable to “go up, go down” because it would reflect that “the
contracts are operating as designed” and added that the Company would “explain that
on a quarterly basis how it’s fluctuating[.]”
ANSWER: Paragraph 84 states a legal conclusion to which no response is
required. To the extent a response is required, Paragraph 84 characterizes or quotes from
ModivCare’s June 23, 2022 Investor Day presentation, and Defendants respectfully refer
the Court to the complete document, which speaks for itself, and deny any allegations
inconsistent therewith. Defendants otherwise deny the allegations in Paragraph 84.
45
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 46 of 269
85. Despite the fluctuation, Defendants claimed that the shift to capitated shared risk
contracts would protect ModivCare’s margins and provide more stability, including by
normalizing working capital and thereby cash flow. 4 Given that the shared risk
contracts’ structure purportedly allowed ModivCare to pass through increased costs
to its customers (thereby protecting ModivCare’s downside risk) while limiting the
Company’s ability to profit from unused services (thereby protecting payors’ downside
risks), Defendants’ characterized its shared risk contracts as “win-win” throughout the
Class Period.
ANSWER: Defendants admit that, during the alleged Class Period, shared-risk
capitated contracts were structured to allow for margin stabilization because generally the
amount of the per-member, per-month fee would be adjusted for the costs to provide the
transportation services. Paragraph 85 characterizes or quotes from ModivCare’s public
statements and SEC filings. Defendants respectfully refer the Court to the complete
recordings and documents, which speak for themselves, and deny any allegations
inconsistent therewith. Except as expressly admitted, Defendants deny the allegations in
Paragraph 85 and footnote 4.
86. Indeed, during the Company’s earnings call for the third quarter of 2022 on November
3, 2022 (the “3Q2022 Earnings Call”), Defendant Sampson explained that
ModivCare’s shared risk contracts allowed the Company to “pass a large chunk” of
“higher cost[s] in [] mobility” onto customers, “protecting the downside in the event that
there’s some volatility in costs or utilization.” Likewise, during the May 10, 2023 Bank
of America Securities Health Care Conference and earnings call for the third quarter
of 2023 on November 3, 2023 (the “3Q2023 Earnings Call”), Sampson explained that
the shared risk contracts’ win-win nature provided ModivCare with “stable rigid
4
[Footnote 4 in Complaint] Working capital is the amount of money a company has
available to operate after deducting its current liabilities (i.e., accounts payable and debt)
from its current assets (i.e., cash, accounts receivable, etc.). See Jason Fernando,
Working Capital: Formula Components, and Limitations, Investopedia (June 17, 2025),
https://www.investopedia.com/terms/w/workingcapital.asp (last accessed Jan. 9, 2026).
46
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 47 of 269
margins regardless of utilization and cost” and “protect[ed] the downside to [the
Company’s] cash flow,” respectively.
ANSWER: Defendants need not respond to the allegations in Paragraph 86 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. Paragraph 86 characterizes or quotes from ModivCare’s
November 3, 2022, May 10, 2023, and November 3, 2023 earnings call and conference
transcripts, and Defendants respectfully refer the Court to the complete recordings of
those earnings calls, which speak for themselves, and deny any allegations inconsistent
therewith. Defendants otherwise deny the allegations in Paragraph 86.
87. Defendants also provided insight into the mechanics of the shared risk true- up
process. For instance, in a slide from ModivCare’s August 2023 investor presentation
(“2Q2023 Investor Presentation”), the Company represented that shared risk
contracts maintained the same net cash flow regardless of utilization due to the
contracts “built-in corridors[,]” which allowed ModivCare to make profit up to a certain
threshold. After that threshold is met, ModivCare stops recognizing revenue and
records a liability within the accrued contract payable account.
ANSWER: Paragraph 87 characterizes or quotes from ModivCare’s Q2 FY2023
investor presentation. Defendants respectfully refer the Court to the complete document,
which speaks for itself, and deny any allegations inconsistent therewith. Defendants
further deny that any alleged statement, knowledge, conduct, document, or omission
allegedly attributable to one defendant is attributable to another. Defendants otherwise
deny the allegations in Paragraph 87.
88. To demonstrate how the corridors function, the Company modeled three utilization
scenarios in the slide. In the low utilization scenario, transportation costs decrease by
47
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 48 of 269
$4 per member with ModivCare recording $2 in a contract payable that it will eventually
repay the customer due to lower costs than anticipated. In the high utilization scenario,
transportation costs increase by $4 per member with ModivCare recording $2 in a
contract receivable that it will eventually receive from the customer to share the higher
than anticipated costs. Based on this, ModivCare represented that the “[s]hared risk
structure reduce[d] income statement impact from changes in costs with the built-in
corridors” (see Figure 2 infra).
ANSWER: Paragraph 88 characterizes or quotes from ModivCare’s Q2 FY2023
investor presentation, and Defendants respectfully refer the Court to the complete
document, which speaks for itself, and deny any allegations inconsistent therewith.
Defendants otherwise deny the allegations in Paragraph 88.
G. During the Class Period, ModivCare’s Free Cash Flow Plummets and
Debt Balloons Due to COVID-19 Rebates, Loss of Customers due to
Service Issues, Increased Utilization, and Collectability Issues
1. ModivCare Reimburses Customers Hundreds of Millions of
Dollars for Low Utilization During COVID-19
48
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 49 of 269
89. Though ModivCare’s NEMT operating income and cash position benefited
significantly from low utilization during the COVID-19 pandemic, those financial
windfalls were offset by swelling contract payables balances leading up to the Class
Period.
ANSWER: Defendants admit that utilization of NEMT services declined during the
COVID-19 pandemic, and that ModivCare’s contract payables balances increased prior
to the start of the alleged Class Period. Except as expressly admitted, Defendants deny
the allegations in Paragraph 89.
90. For instance, according to the FY2020 Form 10-K, ModivCare’s total accrued and
long-term contract payable balances for 2020 was $173,778,000. These balances
represented overpayments and liability reserves related to lower activity due to
COVID-19 and corresponded to ModivCare’s reconciliation and risk corridor contracts
(i.e., ModivCare’s shared risk contracts). In other words, although ModivCare’s shared
risk contracts represented only a portion of ModivCare’s contract mix in 2020, the
Company was responsible for repaying a significant sum as a result of lower utilization
during COVID-19.
ANSWER: Paragraph 90 characterizes or quotes from ModivCare’s FY2020 Form
10-K, and Defendants respectfully refer the Court to the complete document, which
speaks for itself, and deny any allegations inconsistent therewith. Defendants otherwise
deny the allegations in Paragraph 90.
91. By 1Q 2021, ModivCare’s total accrued contract payable balance related to shared
risk contracts had surged to $245,386,000. Given the true-up aspect of its shared risk
contracts, ModivCare anticipated continuing to reimburse those customers for COVID-
19 under-utilization. By contrast, ModivCare did not expect to repay most of its full-
risk customers for COVID-19 related under-utilization. However, according to CW2,
some of ModivCare’s health plan customers requested refunds due to the inactivity
and in some cases, the Company partially refunded payments “in the spirit of good
partnership.”
ANSWER: Paragraph 91 characterizes or quotes from ModivCare’s public
statements or SEC filings, and Defendants respectfully refer the Court to the complete
49
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 50 of 269
documents, which speak for themselves, and deny any allegations inconsistent therewith.
Defendants lack knowledge or information sufficient to form a belief as to the truth of the
CW allegations in Paragraph 91 and deny them on that basis. Defendants otherwise deny
the allegations in Paragraph 91.
92. Indeed, during the Company’s earnings call for the first quarter of 2021 on May 7,
2021 (“1Q2021 Earnings Call”), Defendant Sampson confirmed that ModivCare had
reimbursed some of its full risk customers, stating:
As a reminder, our full risk contracts are structured, so we
bear all the expense management and market fluctuation risk.
Our customers with full risk contract models are fully aware of
the performance during the pandemic.
For some, we have provided or expect to provide
retroactive monetary rebates or prospective rate
concessions. However, for the majority, we do not expect to
provide any concessions.
ANSWER: Paragraph 92 characterizes or quotes from ModivCare’s May 7, 2021
earnings call, and Defendants respectfully refer the Court to the complete recording from
that earnings call, which speaks for itself, and deny any allegations inconsistent therewith.
Defendants otherwise deny the allegations in Paragraph 92.
93. As such, throughout 2021 and leading up to the beginning of the Class Period on
November 3, 2022, ModivCare’s total contracts payable exceeded its net accounts
receivable, as depicted in Figure 3:
50
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 51 of 269
ANSWER: Paragraph 93 and Figure 3 characterize or quote from ModivCare’s
public statements and SEC filings describing its contracts payables and contracts
receivables balances, and Defendants respectfully refer the Court to the complete
recordings and documents, which speak for themselves, and deny any allegations
inconsistent therewith. Defendants otherwise deny the allegations in Paragraph 93 and
Figure 3.
94. At the start of the Class Period, ModivCare began to pay down its massive contract
payables balance. For instance, during the 3Q2022 Earnings Call on November 3,
2022, Defendant Sampson stated that ModivCare “reduced [its] contract payable
balance, net of our contract receivables, by $51 million to a net balance of $184 million”
and added that the Company “expect[ed] to reduce this net balance by an additional
$40 million to $60 million during the fourth quarter” of 2022.
ANSWER: Paragraph 94 characterizes or quotes from ModivCare’s November 3,
2022 earnings call, and Defendants respectfully refer the Court to the complete recording
51
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 52 of 269
from that call, which speaks for itself, and deny any allegations inconsistent therewith.
Defendants otherwise deny the allegations in Paragraph 94.
95. By the end of the fourth quarter of 2022 (“4Q2022”), according to its financial and
operational report for the fourth quarter and full year ended December 31, 2022, which
was filed with the SEC on March 7, 2023 on Form 10-K (the “FY2022 Form 10-K”),
the Company reduced its contract payables to $194.3 million.
ANSWER: Defendants admit that ModivCare filed its FY2022 Form 10-K with the
SEC on March 7, 2023. Paragraph 95 characterizes or quotes from ModivCare’s FY2022
Form 10-K, and Defendants respectfully refer the Court to the complete document, which
speaks for itself, and deny any allegations inconsistent therewith. Except as expressly
admitted, Defendants deny the allegations in Paragraph 95.
96. These payments decimated ModivCare’s cash position. Indeed, after paying $134
million to reduce its contracts payables balance in 2022, the Company ended the
fourth quarter of 2022 with $14.5 million in cash. Nevertheless, Defendants assured
investors that the Company’s cash position would normalize.
ANSWER: Paragraph 96 characterizes or quotes from ModivCare’s FY2022 Form
10-K. Defendants respectfully refer the Court to the complete document, which speaks
for itself, and deny any allegations inconsistent therewith. Defendants further deny that
any alleged statement, knowledge, conduct, document, or omission allegedly attributable
to one defendant is attributable to another. Defendants otherwise deny the allegations in
Paragraph 96.
97. For instance, during the Company’s February 23, 2023 fourth quarter and full-year
2022 earnings call (“FY2022 Earnings Call”), Defendant Shepard stated: “As a
reminder, we expect a more normalized level of activity for these contracts payable
moving forward and, therefore, a more normalized environment for our free cash flow
in 2023.”
52
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 53 of 269
ANSWER: Paragraph 97 characterizes or quotes from ModivCare’s February 23,
2023 earnings call, and Defendants respectfully refer the Court to the complete recording
from that earnings call, which speaks for itself, and deny any allegations inconsistent
therewith. Defendants otherwise deny the allegations in Paragraph 97.
98. Likewise, during the same earnings call, Defendant Sampson represented the
3Q2022 and 4Q2022 payments were the final ones to pay off the balances incurred
under the Company’s shared risk contracts during the COVID-19 pandemic, stating in
relevant part: “2022 involves us paying off the cash that we accumulated on our
balance sheet through COVID in 2020 and 2021 and the bulk of accumulation -- or a
disproportional amount of that accumulation was all paid off in 2022. So the COVID
payoff was finished in 2022.” With COVID-19 payments purportedly complete,
Defendants assured that ModivCare’s working capital fluctuations would normalize
under the shared risk contracts and as a result, the Company would generate more
free cash flow each quarter going forward.
ANSWER: Paragraph 98 characterizes or quotes from ModivCare’s February 23,
2023 earnings call, and Defendants respectfully refer the Court to the complete recording
from that earnings call, which speaks for itself, and deny any allegations inconsistent
therewith. Defendants further deny that any alleged statement, knowledge, conduct,
document, or omission allegedly attributable to one defendant is attributable to another.
Defendants otherwise deny the allegations in Paragraph 98.
2. ModivCare’s NEMT Service Quality Issues and Outdated
Technologies Cause a Swell of Member Complaints, Significant
Customer Issues, and Contract Losses
99. Prior to and throughout the Class Period, ModivCare received increasing complaints
about its NEMT service and technological platforms, which caused payors to be
dissatisfied and led them to place the Company on performance improvement plans
and to delay payments, seek liquidated damages, and cancel contracts.
ANSWER: Defendants need not respond to the allegations in Paragraph 99 to the
extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
53
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 54 of 269
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the allegations concerning
unidentified payors’ states of mind in Paragraph 99 and deny them on that basis.
Defendants otherwise deny the allegations in Paragraph 99.
100. For instance, around 1Q2022, CW1 began hearing that account managers had
“struggles to keep the payors happy.” According to CW1, beginning around May or
June 2022 and continuing throughout CW1’s tenure, ModivCare received increasing
complaints from payors’ members, including reports that drivers were not showing up
on time and of miscommunications between drivers and payors. CW1 recalled that
account managers’ challenges and the increase in member complaints coincided with
Simpson’s appointment as President of the Mobility Division in April 2022, and
explained that with his appointment ModivCare’s NEMT operations changed
dramatically. According to CW1, Simpson began terminating the employment of senior
employees who knew the business really well.
ANSWER: Defendants need not respond to the allegations in Paragraph 100 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
100 and deny them on that basis. Defendants otherwise deny the allegations in
Paragraph 100.
101. CW1 stated that ModivCare’s service quality declined because employees with
“core competencies” – the core leaders who really knew the NEMT business and how
to manage that side of the business – were fired or laid off. CW1 added that payors
54
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 55 of 269
knew and trusted the core leaders, but when they were let go, service quality started
to decline, complaints from payors increased steadily, until the payors decided to quit
ModivCare.
ANSWER: Defendants need not respond to the allegations in Paragraph 101 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
101 and deny them on that basis. Defendants otherwise deny the allegations in
Paragraph 101.
102. Corroborating CW1, CW3 explained that ModivCare laid off approximately 80% of
its customer advocate team and implemented major cost reductions for the operations
team when Simpson arrived at the Company. ModivCare’s customer advocate team
was responsible for supporting the Company’s transportation providers by answering
inquiries, documenting and resolving complaints, and supporting scheduling,
modifying, and canceling reservations.5
ANSWER: Defendants need not respond to the allegations in Paragraph 102 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
5
[Footnote 5 in Complaint] See e.g., FlexJobs, Customer Advocate I ModivCare,
https://www.flexjobs.com/gjw/ModivCare/customer-advocate-i/publicjobs?id=a34c3ad3-
4080-47ef-889c-ae5150395f54 (last accessed Jan. 9, 2026).
55
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 56 of 269
102 and footnote 5 and deny them on that basis. Defendants otherwise deny the
allegations in Paragraph 102 and footnote 5.
103. According to CW3, these staffing cuts eliminated the customer advocate team’s
capability of working with dispatchers to monitor the NEMT trips live and, as a result,
ModivCare’s ability to address service issues was diminished. For example, CW3
described that certain technologies of ModivCare’s software, such as GPS tracking
and dynamic reassignment (meaning a NEMT trip would be automatically re-booked
if a driver was unavailable), required dedicated staff advocates because the electronic
systems were “plagued by bugs” throughout CW3’s tenure and could not fulfill these
capabilities without human intervention.
ANSWER: Defendants need not respond to the allegations in Paragraph 103 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
103 and deny them on that basis. Defendants otherwise deny the allegations in
Paragraph 103.
104. Accordingly, when CW3 heard that the advocate team was eliminated entirely,
CW3 knew ModivCare did not have the resources to deliver technological
enhancements that the Company promised to payors. As a result, CW3 stated that
payors began to consistently express dissatisfaction with ModivCare’s service and
inquire about no shows and on-time performance issues. CW3 confirmed ModivCare’s
payors continued to express their dissatisfaction throughout CW3’s tenure.
Specifically, CW3 recalled that ModivCare’s local Operations teams in Virginia and
Florida lacked capabilities to address service issues, and that no-shows, on-time
performance, and overall declining performance were issues in New Jersey.
ANSWER: Defendants need not respond to the allegations in Paragraph 104 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
56
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 57 of 269
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
104 and deny them on that basis. Defendants otherwise deny the allegations in
Paragraph 104.
105. When asked whether payors refused to pay or delayed payment due to service
issues, CW1 responded “absolutely” and explained that if service levels were not met,
ModivCare would bear the cost. CW1 added that, throughout the last year of CW1’s
employment, ModivCare was failing to meet targets for member satisfaction KPIs,
including on-time performance, no-show rates, cancellation ratios, and call-center
responsiveness KPIs.
ANSWER: Defendants need not respond to the allegations in Paragraph 105 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
105 and deny them on that basis. Defendants otherwise deny the allegations in
Paragraph 105.
106. CW3 likewise explained that KPIs, such as on time performance, NVA (no vehicle
available), and complaint volume, were important to ModivCare’s payors. CW3 added
that ModivCare consistently failed to meet KPIs, including on-time performance and
NVAs (which caused missed rides), throughout CW3’s tenure.
ANSWER: Defendants need not respond to the allegations in Paragraph 106 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
57
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 58 of 269
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
106 and deny them on that basis. Defendants otherwise deny the allegations in
Paragraph 106.
107. CW1 recounted three key trends during CW1’s tenure with ModivCare: payors
cancelling contracts; leadership getting concerned with revenue coming in, because
contracts were being cancelled; and increased concern with operational performance.
ANSWER: Defendants need not respond to the allegations in Paragraph 107 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
107 and deny them on that basis. Defendants otherwise deny the allegations in
Paragraph 107.
108. CW1 explained that, during CW1’s last year with ModivCare, the Company began
losing NEMT contracts due to service complaints. CW1 added that ModivCare’s
service levels “were way down” due to poor service quality and high employee
turnover. Indeed, CW1 stated during this time, payors were “literally cancelling
contracts because the service, and the people trying to perform the services, kept
changing so much. The service levels were way down.” CW1 specifically recalled that
payors, such as UnitedHealthcare and HCSC, cancelled services due to ModivCare’s
failure to meet member satisfaction KPIs.
58
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 59 of 269
ANSWER: Defendants need not respond to the allegations in Paragraph 108 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
108 and deny them on that basis. Defendants otherwise deny the allegations in
Paragraph 108.
109. CW1 also described attending a standing, direct report staff meeting with leaders
from Operations, Client Services, Process Optimization, Human Resources, Finance,
Project Management, and Strategy during the summer of 2022 where the rise in
service complaints and payors’ disappointment over the rise in service complaints
were being discussed. CW1 explained that meeting attendees were specifically
discussing members not feeling comfortable with drivers, increased member
complaints including those about vehicle conditions, member satisfaction concerns,
and service level agreements.
ANSWER: Defendants need not respond to the allegations in Paragraph 109 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
109 and deny them on that basis. Defendants otherwise deny the allegations in
Paragraph 109.
110. During the meeting, according to CW1, Simpson told attendants that ModivCare
only owned “picking up and dropping” off the member and specifically did not “own the
59
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 60 of 269
customer experience.” According to CW1, Simpson likened transporting members to
Amazon’s process for getting packages where they need to go during the meeting. It
was at this time, according to CW1, that it became clear to CW1 that ModivCare could
be headed for financial troubles since member experience was critical to the NEMT’s
business’ success, but was specifically de-prioritized. CW1 described Simpson’s
directive to ModivCare’s operational leaders as “shocking” and said, “that was the
moment in time I realized we could be in trouble.”
ANSWER: Defendants need not respond to the allegations in Paragraph 110 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
110 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph
110.
111. CW1 explained that Simpson’s stance that ModivCare was not responsible for
members’ experience “100%” contributed to the loss of business. CW1 explained that
running the company became very difficult, as employees with knowledge about
operations were pushed out, and payors became increasingly dissatisfied. CW1
added that ModivCare’s abandonment of its core values, such as serving members
and firing NEMT experts, and the subsequent rise in complaints, all resulted in the
loss of contracts.
ANSWER: Defendants need not respond to the allegations in Paragraph 111 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
60
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 61 of 269
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
111 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph
111.
112. Corroborating CW1, CW2 attributed ModivCare’s damaged payor relationships to
ModivCare’s new leadership, after former-CEO Daniel Greenleaf departed the
Company in August 2022, treating the Company as a logistics operation— focusing
narrowly on financials and prioritizing profit over customer service—despite it being a
people-driven service business.
ANSWER: Defendants need not respond to the allegations in Paragraph 112 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants admit that
Daniel Greenleaf was ModivCare’s former CEO. Defendants lack knowledge or
information sufficient to form a belief as to the truth of the CW allegations in Paragraph
112 and deny them on that basis. Except as expressly admitted, Defendants deny the
allegations in Paragraph 112.
113. CW1 also recounted that ModivCare’s service issues resulted in a lot of problems
with the Big 6, which included UnitedHealthcare, among others. CW1 recalled, during
the last year of CW1’s tenure, that the payors’ executives would bring concerns to
ModivCare’s operations team but the operations team was often unprepared to
respond to their concerns. CW1 said that this “absolutely” contributed to the loss of
contracts.
ANSWER: Defendants need not respond to the allegations in Paragraph 113 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
61
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 62 of 269
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
113 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph
113.
114. When asked whether payors raised these service issues with CW1, CW1 replied
“all the time.” CW1 also heard about the service issues, including drivers not picking
members up on time and miscommunications between drivers and members, from the
operations team, executive teams, and “everyone across the country, weekly.” CW1
confirmed that the service issues were 100% on Shepard’s and Sampson’s radars.
ANSWER: Defendants need not respond to the allegations in Paragraph 114 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
114 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph
114.
115. CW2 also confirmed that ModivCare quantified its customer service failures,
explaining that call center performance was tracked. CW2 stated that, beginning
around 2Q2022 and continuing throughout CW2’s tenure, ModivCare’s poor
operational performance (such as call center failures) led to payor dissatisfaction and
monthly liquidated damages of hundreds of thousands of dollars. CW2 stated that
these service issues were discussed frequently during Monthly Leadership Meetings.
ANSWER: Defendants need not respond to the allegations in Paragraph 115 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
62
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 63 of 269
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
115 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph
115.
116. Similarly, CW3 stated ModivCare consistently failed to provide payors with the
technology and system maintenance offerings that the Company committed to
delivering in contracts, including ride scheduling, real-time reporting, GPS tracking,
and dynamic trip reassignment for medical appointments. Indeed, according to CW3,
by the end of CW3’s tenure at ModivCare, the Company still remained dependent on
the outdated LogistiCare platform,6 despite spending millions of dollars, over an eight-
year period, on supposed upgrades.
ANSWER: Defendants need not respond to the allegations in Paragraph 116 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants admit that on
January 6, 2021, ModivCare changed its name from Providence Service Corporation to
ModivCare, Inc. Defendants lack knowledge or information sufficient to form a belief as
to the truth of the CW allegations in Paragraph 116 and deny them on that basis. Except
as expressly admitted, Defendants deny the allegations in Paragraph 116 and footnote 6.
6
[Footnote 6 in Complaint] On January 6, 2021, the Company was rebranded from
Providence Service Corporation to ModivCare Inc. and as a part of this rebrand, the
Company’s wholly-owned NEMT subsidiary, LogistiCare Solutions, LLC, was rebranded
to ModivCare Solutions, LLC.
63
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 64 of 269
117. CW3 learned about payors’ complaints that ModivCare was not fulfilling its
commitments from interactions with ModivCare’s local Operations Managers or
Regional Vice Presidents when the Company began preparations to respond to a new
request for proposal (“RFP”). CW3 provided an example where ModivCare promised
Virginia-based payors certain technological enhancements, such as a new user
interface for the call center, in connection with a 2018 RFP. According to CW3,
between 2020 and 2023 while preparing for the next rounds of RFPs, the local
Operations Manager raised that these 2018 promises remained unfulfilled, and that
the client had complained about the lack of enhancements previously guaranteed
during the earlier RFP.
ANSWER: Defendants need not respond to the allegations in Paragraph 117 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
117 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph
117.
118. CW3 also explained that missed appointments and no-shows were significant
service issues that ModivCare had throughout CW3’s tenure but did not improve on.
Indeed, CW3 participated in series of communications with Simpson, the President of
Mobility, during the Spring of 2022 to create a roadmap with technology
enhancements as part of ModivCare’s RFPs to state MCO clients, specifically in
response to complaints. Specifically, the roadmap contemplated: GPS tracking with
real-time trip assignment to reduce no-shows or late arrivals by transportation
providers; improvements to claims so providers could process payments instantly or
within 7–14 days; and real- time reporting that would have allowed payors to view on-
time performance, complaints, and vehicle availability. Yet, despite promising payors
that the Company had such capabilities in its RFPs during the Class Period, the
Company never delivered on providing these technological enhancements
during CW3’s tenure. Indeed, CW3 stated that the technological enhancements in
64
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 65 of 269
the roadmap never materialized and instead, the Company’s systems had not been
improved since 2016 and were pieced together with no enhancements.
ANSWER: Defendants need not respond to the allegations in Paragraph 118 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
118 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph
118.
119. As a result, CW3 likewise stated that ModivCare’s poor service delivery, long-
standing weaknesses in technology, and reliance on an outdated platform caused
major contracts to be under threat throughout CW3’s tenure. Indeed, between
November 2022 and the end of CW3’s tenure in September 2023, CW3 held several
meetings with ModivCare’s leadership, including Defendant Sampson, during which
CW3 warned leadership that the Company’s contracts were at risk because they were
failing to keep up with their competitors.
ANSWER: Defendants need not respond to the allegations in Paragraph 119 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
119 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph
119.
65
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 66 of 269
120. Specifically, CW3 issued such a warning to Defendant Sampson during a week-
long, in-person Summit in May 2023 at ModivCare’s Denver headquarters, which was
attended by CW3, Defendant Sampson, the President of ModivCare’s Mobility
Division Simpson, the Senior VP/Head of Mobility Product Edward Hoffman, and “the
full c-suite” (the “May 2023 Summit”). During the May 2023 Summit, CW3’s team
presented competitive analyses that compared ModivCare’s offerings to competitors
and emphasized long-standing weaknesses in technology, poor service delivery, and
a disjointed operational model based on the outdated LogistiCare platform.
ANSWER: Defendants need not respond to the allegations in Paragraph 120 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;
see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge
or information sufficient to form a belief as to the truth of the CW allegations in Paragraph
120 and deny them on that basis. Defendants otherwise deny the allegations in
Paragraph 120.
121. CW3 explained that Senior VP of Government Affairs Robert Pittman, Senior VP
of Mobility Edward Hoffman, and Defendant Sampson instructed CW3 to highlight
capabilities to customers in RFPs that did not exist, including technology platforms the
company had long promised but never delivered. Indeed, CW3 stated that the
guidance to CW3’s team was to continue to falsely represent ModivCare’s capabilities
in RFP even when the technology was not yet implemented or would never be. CW3
added the RFPs were essentially highlighting vaporware.7
ANSWER: Defendants need not respond to the allegations in Paragraph 121 to
the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and
7
[Footnote 7 in Complaint] Vaporware refers to “a computer-related product that has
been widely advertised but has not and may never become available.” See Merriam-
Webster, vaporware, https://www.merriam-webster.com/dictionary/vaporware (last
accessed Jan. 9, 2026).
66
Case No. 1:25-cv-00306-GPG-KAS Document 79 filed 10/05/26 USDC Colorado
pg 67 of 269
10-Q risk disclosures, which are the only alleged misstatements that the Court addressed
in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5Showing the first 150,000 of 628,868 characters. Full text.